Document:

EX-10.55

 Exhibit 10.55 

Execution Version 

STOCK PURCHASE AGREEMENT 

THIS STOCK PURCHASE AGREEMENT
(“Agreement”) is entered into as of April 5, 2020 (the “Execution Date”), by and between Glaxo Group Limited, a private limited liability company incorporated under the laws of England
and Wales having an office at 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom (“GSK”), and Vir Biotechnology, Inc. a Delaware corporation having an office at 499 Illinois Street, Suite 500, San
Francisco, CA 94158 (“Vir”). The capitalized terms used herein and not otherwise defined have the meanings given to them in Appendix 1. 

RECITALS 

Vir has agreed to sell, and GSK has agreed to purchase, shares of Common Stock subject to and in accordance with the terms and provisions of
this Agreement. 
 Contemporaneously with the execution of this Agreement, GlaxoSmithKline Intellectual Property Development Limited and
GlaxoSmithKline Biologicals SA, Affiliates of GSK, and Vir are entering into that certain preliminary agreement set forth in Appendix 2 containing the terms agreed by such parties to govern their strategic collaboration to develop,
manufacture and commercialize antibody products, vaccine products and functional genomic products in the Field (as defined below) (the “Preliminary Collaboration Agreement”) until such time as the Preliminary Collaboration
Agreement is expanded into a longer form definitive collaboration agreement mutually agreed, and entered into, by the parties to the Preliminary Collaboration Agreement (the “Definitive Collaboration Agreement”). 

AGREEMENT 

For good and valuable consideration, GSK and Vir agree as follows: 
  

	Section	 1. SALE AND PURCHASE OF STOCK

 1.1    Purchase of Stock. Subject to the terms and conditions of this Agreement,
at the Closing, Vir will issue and sell to GSK, and GSK will purchase from Vir, 6,626,027 shares of Common Stock (the “Shares”) at a price per share equal to $37.73 for an aggregate purchase price of $249,999,998.71 (the
“Purchase Price”). 
 1.2    Payment. At the Closing, GSK will pay the Purchase
Price by wire transfer of immediately available funds in accordance with wire instructions, which instructions will have been provided by Vir to GSK at least three (3) Business Days prior to the Closing, and Vir will deliver the Shares in
restricted book-entry form to GSK. 
 1.3    Closing. 

(a)    Closing. The closing of the transaction contemplated by Section 1.1 (the
“Closing”) will be held at the offices of Vir or through the electronic exchange of documents and signatures, as promptly as practicable, and in no event more than five (5) Business Days after the conditions to the
Closing set forth in Section 7 are satisfied or waived for the Closing (other than those conditions that by their nature are to be satisfied or waived at the Closing) or at such other place, if any, time and/or date as may
be jointly designated by GSK and Vir for the Closing. 

 (b)    Closing Deliverables. 

(i)    At the Closing, Vir will deliver to GSK: 

A.    a duly executed cross-receipt in form and substance reasonably satisfactory to each party (the
“Cross-Receipt”); 
 B.    a certificate in form and substance reasonably satisfactory
to GSK and duly executed on behalf of Vir by an authorized officer of Vir, certifying that the conditions to the Closing set forth in Section 7.2(a), (b), (c) and (d) of this Agreement have been
fulfilled; and 
 C.    a certificate of the secretary of Vir dated as of the Closing Date certifying that
attached thereto is a true and complete copy of all resolutions adopted by the Board authorizing the execution, delivery and performance of this Agreement and the transactions contemplated herein and that all such resolutions are in full force and
effect and are all the resolutions adopted in connection with the transactions contemplated hereby as of the Closing Date. 

(ii)    At the Closing, GSK will deliver to Vir: 

A.    a duly-executed Cross-Receipt; and 

B.    a certificate in form and substance reasonably satisfactory to Vir and duly executed on behalf of GSK by an
authorized officer of GSK, certifying that the conditions to the Closing set forth in Section 7.1(b) and (c) of this Agreement have been fulfilled. 

 

	Section	 2. REPRESENTATIONS AND WARRANTIES OF
VIR 

 Except as otherwise specifically contemplated by this Agreement, Vir hereby represents and
warrants to GSK that: 
 2.1    Private Placement. Neither Vir nor any Person acting on its behalf, has,
directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under any circumstances that would require registration of the Shares under the Securities Act. Subject to the accuracy of the
representations made by GSK in Section 3, the Shares will be issued and sold to GSK in compliance with applicable exemptions from the registration and prospectus delivery requirements of the Securities Act and the
registration and qualification requirements of all applicable securities Laws of the states of the United States. Vir has not engaged any brokers, finders or agents, or incurred, or will incur, directly or indirectly, any liability for brokerage or
finder’s fees or agents’ commissions or any similar charges in connection with this Agreement and the transactions contemplated hereby. 

2.2    Organization and Qualification. Vir is duly incorporated, validly existing and in good standing under
the laws of the State of Delaware, with full corporate power and authority to 

  
 2 

 
conduct its business as currently conducted. Vir is duly qualified to do business and is in good standing in every jurisdiction in which the nature of the business conducted by it or property
owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, would not reasonably be expected to have a Material Adverse Effect on Vir. 

2.3    Authorization; Enforcement. Vir has all requisite corporate power and authority to enter into and to
perform its obligations under this Agreement, to consummate the transactions contemplated hereby and to issue the Shares in accordance with the terms hereof. The execution, delivery and performance of this Agreement by Vir and the consummation by it
of the transactions contemplated hereby (including the issuance of the Shares at the Closing in accordance with the terms hereof) have been duly authorized by the Board and no further consent or authorization of Vir, the Board, or its stockholders
is required. This Agreement has been duly executed by Vir and constitutes a legal, valid and binding obligation of Vir enforceable against Vir in accordance with its terms, except as enforceability may be limited by applicable bankruptcy,
insolvency, reorganization, or moratorium or similar Laws affecting creditors’ and contracting parties’ rights generally. 

2.4    Issuance of Shares. The Shares are duly authorized and, upon issuance in accordance with the terms of
this Agreement, will be validly issued, fully paid and non-assessable and will not be subject to preemptive rights or other similar rights of stockholders of Vir. 

2.5    SEC Documents, Financial Statements. 

(a)    The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act. Vir has delivered
or made available (by filing on the SEC’s electronic data gathering and retrieval system (EDGAR)) to GSK complete copies of its most recent Annual Report on Form 10-K, and any report on Form 8-K, in each case filed with the SEC after October 10, 2019 and prior to the Execution Date (the “SEC Documents”). As of its date, each SEC Document complied in all material respects
with the requirements of the Exchange Act, and other Laws applicable to it, and, as of its date, such SEC Document did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in
order to make the statements therein, in light of the circumstances under which they were made, not misleading. No inquiries or any other investigation conducted by or on behalf of GSK or its representatives or counsel will modify, amend or
affect GSK’s right to rely on the truth, accuracy and completeness of the SEC Documents and Vir’s representations and warranties contained in this Agreement. 

(b)    The financial statements, together with the related notes and schedules, of Vir included in the SEC
Documents comply as to form in all material respects with all applicable accounting requirements and the published rules and regulations of the SEC and all other applicable rules and regulations with respect thereto. Such financial statements,
together with the related notes and schedules, have been prepared in accordance with GAAP applied on a consistent basis during the periods involved (except (i) as may be otherwise indicated in such financial statements or the notes thereto or
(ii) in the case of unaudited interim statements, to the extent they may not include footnotes or may be condensed or summary statements), and fairly present in all material respects the financial condition of Vir and its consolidated
subsidiaries as of the dates thereof and the results of operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments). 

  
 3 

 (c)    The Common Stock is listed on Nasdaq, and Vir has taken no
action designed to, or that to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act or delisting the Common Stock from Nasdaq. As of the date of this Agreement, Vir has not received
any notification that, and has no knowledge that, the SEC or Nasdaq is contemplating terminating such registration or listing. 

2.6    Internal Controls; Disclosure Controls and Procedures. Vir maintains internal control over
financial reporting as defined in Rule 13a-15(f) under the Exchange Act. Vir has implemented the “disclosure controls and procedures” (as defined in Rules
13a-15(e) and 15d-15(e) under the Exchange Act) required in order for the principal executive officer and principal financial officer of Vir to engage in the review and
evaluation process mandated by the Exchange Act, and is in compliance with such disclosure controls and procedures in all material respects. Each of the principal executive officer and the principal financial officer of Vir has made all
certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002 with respect to all reports, schedules, forms, statements and other documents required to be filed by Vir with the SEC. 

2.7    Capitalization and Voting Rights. 

(a)    The authorized capital of Vir as of the date hereof consists of: (i) 300,000,000 shares of Common Stock
of which, as of April 5, 2020, (A) 109,821,390 shares were issued and outstanding, (B) 11,925,151 shares were reserved for issuance pursuant to Vir’s equity incentive plans (including its stock purchase plan) described in the SEC
Documents, (C) 244,444 shares were reserved for issuance pursuant to outstanding warrants, and (D) 7,894,104 shares were issuable upon the exercise of stock options outstanding, and (ii) 10,000,000 shares of Preferred Stock, of which no shares are
issued and outstanding as of the date of this Agreement. All of the issued and outstanding shares of Common Stock (1) have been duly authorized and validly issued, (2) are fully paid and
non-assessable and (3) were issued in compliance with all applicable federal and state securities Laws and not in violation of any preemptive rights. 

(b)    All of the authorized shares of Common Stock are entitled to one (1) vote per share. 

(c)    Except as described or referred to in the SEC Documents, as of April 4, 2020, there were not:
(i) any outstanding equity securities, options, warrants, rights (including conversion or preemptive rights) or other agreements pursuant to which Vir is or may become obligated to issue, sell or repurchase any shares of its capital stock or
any other securities of Vir other than equity securities that may have been granted pursuant to its equity incentive plans, which plans are described in the SEC Documents; or (ii) any restrictions on the transfer of capital stock of Vir other
than pursuant to federal or state securities Laws or as set forth in this Agreement. 
 (d)    Vir is not a party
to or subject to any agreement or understanding relating to the voting of shares of capital stock of Vir or the giving of written consents by a stockholder or director of Vir. 

  
 4 

 2.8    No Conflicts; Government Consents and Permits. 

(a)    The execution, delivery and performance of this Agreement by Vir and the consummation by Vir of the
transactions contemplated hereby (including the issuance of the Shares) will not (i) conflict with or result in a violation of any provision of Vir’s Amended and Restated Certificate of Incorporation or Amended and Restated Bylaws, each as
in effect on the date hereof, (ii) violate or conflict with, or result in a breach of any provision of, or constitute a default under, any agreement, indenture, or instrument to which Vir is a party, or (iii) result in a violation of any
Law (including United States federal, state and U.K. securities Laws and regulations and regulations of any self-regulatory organizations) applicable to Vir, except in the case of clauses (ii) and (iii) only, for such conflicts,
breaches, defaults, and violations as would not reasonably be expected to have, a Material Adverse Effect on Vir or result in a liability for GSK. 

(b)    Vir is not required to obtain any consent, authorization or order of, or make any filing or registration
with, any court or governmental agency or any regulatory agency or self-regulatory organization in order for it to execute, deliver or perform any of its obligations under this Agreement in accordance with the terms hereof, or to issue and sell the
Shares in accordance with the terms hereof other than such as have been made or obtained, and except for (i) any post-closing filings required to be made under federal or state securities Laws, (ii) any required filings or notifications
regarding the issuance or listing of additional shares with Nasdaq, and (iii) the applicable premerger notification and waiting period requirements of the HSR Act, and such other Antitrust Law as may be applicable to the Agreement. 

2.9    Litigation. Other than as set forth in the SEC Documents filed prior to the date of this Agreement,
there is no action, suit, proceeding or investigation pending (of which Vir has received notice or otherwise has knowledge) or, to Vir’s knowledge, threatened, against Vir or that Vir intends to initiate, except where such action, suit,
proceeding or investigation, as the case may be, and would not reasonably be expected to have a Material Adverse Effect. 

2.10    Licenses and Other Rights; Compliance with Laws. Vir has all franchises, permits, licenses and other
rights and privileges (“Permits”) necessary to permit it to own its properties and to conduct its business as presently conducted and is in compliance thereunder, except where the failure to be in compliance would not
reasonably be expected to have, a Material Adverse Effect. Vir has not taken any action that would interfere with its ability to renew all such Permit(s), except where the failure to renew such Permit(s) would not reasonably be expected to have, a
Material Adverse Effect. Vir is and has been in compliance with all Laws applicable to its business, properties and assets, and to the products and services sold by it, except where the failure to be in compliance has not had and would not
reasonably be expected to have a Material Adverse Effect. 
 2.11    Intellectual Property. 

(a)    The Intellectual Property that is owned by Vir or its subsidiaries is owned free from any Liens or
restrictions. All of Vir’s material Intellectual Property Licenses are in full force and effect in accordance with their terms, are free of any Liens or restrictions, and, to Vir’s knowledge, neither Vir, nor any other party thereto, is in
material breach of any such material Intellectual Property License. To Vir’s knowledge, no event has occurred that with notice or lapse 

  
 5 

 
of time or both (i) would constitute a breach or default of any such material Intellectual Property License, (ii) would result in the termination thereof, or (iii) would cause or
permit the acceleration or other change of any right or obligation or the loss of any benefit thereunder by Vir or its subsidiaries except in the case of each of clauses (i) through (iii) as would not reasonably be expected to
have a Material Adverse Effect. 
 (b)    Except as set forth in the SEC Documents, there is no legal claim or
demand of any Person or any proceeding that is pending or threatened in writing, (i) challenging the right of Vir in respect of any Intellectual Property of Vir, or (ii) claiming that any default exists under any Intellectual Property
License, except, in the case of clauses (i) and (ii) above, where any such claim, demand or proceeding has not had, and would not reasonably be expected to have, a Material Adverse Effect. 

(c)    Except as set forth in the SEC Documents: (i) Vir or one of its subsidiaries owns, free and clear of
any Lien or encumbrance, or, to Vir’s knowledge, has a valid license, or an enforceable right to use, as it is used or held for use, all U.S. and non-U.S. patents, trade secrets, know-how, trademarks, service marks, copyrights, and other proprietary and Intellectual Property rights, and all grants and applications with respect to the foregoing (collectively, the “Proprietary
Rights”) necessary for the conduct of Vir’s business, except where the failure to own or have any of the foregoing would not reasonably be expected to have, a Material Adverse Effect (such Proprietary Rights owned by or licensed to
Vir collectively, the “Vir Rights”); and (ii) Vir and its subsidiaries have taken reasonable measures to protect the Vir Rights, consistent with prudent commercial practices in the biotechnology industry,
except where failure to take such measures has not had, and would not reasonably be expected to have, a Material Adverse Effect. 

2.12    Health Care Matters. Vir: (i) has operated and currently operates its business in compliance in
all material respects with applicable provisions of the Health Care Laws (as defined below) of the Food and Drug Administration (“FDA”), the Department of Health and Human Services and any comparable state, foreign or other
regulatory authority to which they are subject (collectively, the “Applicable Regulatory Authorities”) applicable to the ownership, testing, development, manufacture, packaging, processing, use, sale, promotion, distribution,
storage, import, export or disposal of any of Vir’s product candidates or any product manufactured or distributed by Vir; (ii) has not received any FDA Form 483, written notice of adverse finding, warning letter, untitled letter or other
correspondence or written notice from any court or arbitrator or the Applicable Regulatory Authorities alleging or asserting non-compliance with any licenses, certificates, approvals, clearances, exemptions,
authorizations, permits and supplements or amendments thereto required by any such Health Care Laws (“Regulatory Authorizations”); (iii) possesses all Regulatory Authorizations required to conduct its business as currently
conducted and such Regulatory Authorizations are valid and in full force and effect and Vir is not in violation, in any material respect, of any term of any such Regulatory Authorizations; (iv) has not received notice of any claim, action,
suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or the Applicable Regulatory Authorities or any other third party alleging that any product operation or activity is in material
violation of any Health Care Laws and has no knowledge that the Applicable Regulatory Authorities or any other third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; (v) has not received
notice that any of the Applicable Regulatory Authorities has taken, is taking or intends to take action to limit, suspend, modify or revoke any material Regulatory 

  
 6 

 
Authorizations and has no knowledge that any of the Applicable Regulatory Authorities is considering such action; (vi) has filed, obtained, maintained or submitted all material reports,
documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws or Regulatory Authorizations and that all such reports, documents, forms, notices, applications, records, claims,
submissions and supplements or amendments were materially complete and correct on the date filed (or were materially corrected or supplemented by a subsequent submission); (vii) is not a party to and does not have any ongoing reporting obligations
pursuant to any corporate integrity agreements, deferred prosecution agreements, monitoring agreements, consent decrees, settlement orders, plans of correction or similar agreements with or imposed by any Applicable Regulatory Authority; and
(viii) along with its employees, officers and directors, has not been excluded, disqualified, suspended or debarred from participation in any government health care program or human clinical research or, to Vir’s knowledge, is subject to a
governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, disqualification or exclusion. 

2.13    Clinical Trials. None of Vir’s product candidates has received marketing approval from any
Applicable Regulatory Authority. All clinical and pre-clinical studies and trials conducted by or on behalf of or sponsored by Vir, or in which Vir has participated, with respect to Vir’s product
candidates, including any such studies and trials that are described in the SEC Documents, or the results of which are referred to in the SEC Documents, as applicable (collectively, “Company Trials”), were, and if still
pending are, to Vir’s knowledge, being conducted in all material respects in accordance with all applicable Health Care Laws of the Applicable Regulatory Authorities, including the FDA’s current Good Clinical Practices and Good Laboratory
Practices, standard medical and scientific research procedures and any applicable rules, regulations and policies of the jurisdiction in which such trials and studies are being conducted. The descriptions in the SEC Documents of the results of any
Company Trials are accurate and complete descriptions in all material respects and fairly present the data derived therefrom. Vir has no knowledge of any other studies or trials not described in the SEC Documents, the results of which are
inconsistent with or call into question the results described or referred to in the SEC Documents. Vir has not received any written notices, correspondence or other communications from the Applicable Regulatory Authorities or any other governmental
entity or any institutional review board (“IRB”) or independent ethics committee (“IEC”) requiring or threatening the termination, material modification or suspension of Company Trials, other than
ordinary course communications with respect to modifications in connection with the design and implementation of such studies or trials, and, to Vir’s knowledge, there are no reasonable grounds for the same. No investigational new drug
application or comparable submission filed by or on behalf of Vir with the FDA has been terminated or suspended by the FDA or any other Applicable Regulatory Authority. Vir has obtained (or caused to be obtained) informed consent by or on behalf of
each human subject who participated in a Company Trial, and Vir has obtained (or caused to be obtained) applicable IRB or IEC approvals for each Company Trial. To Vir’s knowledge, none of the Company Trials involved any investigator who has
been disqualified as a clinical investigator or has been found by the FDA to have engaged in scientific misconduct. 

  
 7 

 2.14    Absence of Certain Changes. 

(a)    Except as disclosed in the SEC Documents filed prior to the Execution Date, since December 31, 2019, no
change or event has occurred, except where such change or event has not had, and would not reasonably be expected to have, a Material Adverse Effect on Vir. 

(b)    Except as set forth in the SEC Documents filed prior to the Execution Date or as contemplated by this
Agreement or the Preliminary Collaboration Agreement, since December 31, 2019, Vir has not (i) declared or paid any dividends, or authorized or made any distribution upon or with respect to any class or series of its capital stock, or
(ii) sold, exchanged or otherwise disposed of any of its material assets or rights. 
 (c)    Since
December 31, 2019, Vir has not admitted in writing its inability to pay its debts generally as they become due, filed or consented to the filing against it of a petition in bankruptcy or a petition to take advantage of any insolvency act, made
an assignment for the benefit of creditors, consented to the appointment of a receiver for itself or for the whole or any substantial part of its property, or had a petition in bankruptcy filed against it, been adjudicated a bankrupt, or filed a
petition or answer seeking reorganization or arrangement under the federal bankruptcy Laws or any other Laws of the United States or any other jurisdiction. 

2.15    Not an Investment Company. Vir is not, and after receipt of the Purchase Price, will not be, an
“investment company” as defined in the Investment Company Act of 1940, as amended. 

2.16    Critical Technology. Vir does not produce, design, test, manufacture, fabricate, or develop one or
more “critical technologies” within the meaning of the Defense Production Act of 1950, as amended, including all implementing regulations thereof. 

2.17    No Integration. Vir has not, directly or through any agent, sold, offered for sale, solicited offers
to buy or otherwise negotiated in respect of, any security (as defined in the Securities Act) that is or will be integrated with the Shares sold pursuant to this Agreement in a manner that would require the registration of the Shares under the
Securities Act. 
  

	Section	 3. REPRESENTATIONS AND WARRANTIES OF GSK

 Except as otherwise specifically contemplated by this Agreement, GSK hereby represents and warrants to Vir that:

 3.1    Authorization; Enforcement. GSK has the requisite corporate or other similar power and authority
to enter into this Agreement and to consummate the transactions contemplated hereby. GSK has taken all necessary corporate or other similar action to authorize the execution, delivery and performance of this Agreement. Upon the execution and
delivery of this Agreement, this Agreement will constitute a valid and binding obligation of GSK enforceable against GSK in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization,
moratorium or similar Laws affecting creditors’ and contracting parties’ rights generally. 

  
 8 

 3.2    No Conflicts; Government Consents and Permits. 

(a)    The execution, delivery and performance of this Agreement by GSK and the consummation by GSK of the
transactions contemplated hereby (including the purchase of the Shares) will not (i) conflict with or result in a violation of any provision of GSK’s memorandum and articles of association or equivalent organizational documents,
(ii) violate or conflict with, or result in a breach of any provision of, or constitute a default under, any agreement, indenture, or instrument to which GSK is a party, or (iii) result in a violation of any Law (including U.S. federal and
state and U.K. securities Laws and regulations and regulations of any self-regulatory organizations) applicable to GSK, except in the case of clauses (ii) and (iii) only, for such conflicts, breaches, defaults, and violations as
have not had, and would not reasonably be expected to have, a Material Adverse Effect on GSK or result in a liability for Vir. 

(b)    GSK is not required to obtain any consent, authorization or order of, or make any filing or registration
with, any court or governmental agency or any regulatory agency or self-regulatory organization in order for it to execute, deliver or perform any of its obligations under this Agreement in accordance with the terms hereof, or to purchase the Shares
in accordance with the terms hereof other than such as have been made or obtained except for the applicable premerger notification and waiting period requirements of the HSR Act, and such other Antitrust Law as may be applicable to the Agreement.

 3.3    Investment Purpose. GSK is purchasing the Shares for its own account and not with a present view
toward the public distribution thereof and has no arrangement or understanding with any other Persons regarding the distribution of such Shares except as would not result in a violation of the Securities Act. GSK will not, directly or indirectly,
offer, sell, pledge, transfer or otherwise dispose of (or solicit any offers to buy, purchase or otherwise acquire or take a pledge of) any of the Shares except in accordance with the Securities Act and to the extent permitted by
Section 6.1 and Section 6.2. 
 3.4    Reliance on
Exemptions. GSK understands that Vir intends for the Shares to be offered and sold to it in reliance upon specific exemptions from the registration requirements of United States federal and state securities Laws and that Vir is relying upon the
truth and accuracy of, and GSK’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of GSK set forth herein in order to determine the availability of such exemptions and the eligibility of GSK to
acquire the Shares. 
 3.5    Accredited Investor; Access to Information. GSK is an “accredited
investor” as defined in Regulation D under the Securities Act and is knowledgeable, sophisticated and experienced in making, and is qualified to make decisions with respect to investments in shares presenting an investment decision like that
involved in the purchase of the Shares. GSK has been furnished with materials relating to the offer and sale of the Shares that have been requested by GSK, including the SEC Documents, and GSK has had the opportunity to review the SEC Documents. GSK
has been afforded the opportunity to ask questions of Vir. Neither such inquiries nor any other investigation conducted by or on behalf of GSK or its representatives or counsel will modify, amend or affect GSK’s right to rely on the truth,
accuracy and completeness of the SEC Documents and Vir’s representations and warranties contained in this Agreement. 

3.6    Restricted Securities. GSK understands that the Shares will be characterized as “restricted
securities” under the U.S. federal securities Laws inasmuch as they are being acquired 

  
 9 

 
from Vir in a private placement under Section 4(a)(2) of the Securities Act and that under such Laws and applicable regulations such Shares may be resold without registration under the
Securities Act only in certain limited circumstances. 
 3.7    Foreign Purchaser. GSK is not a United
States person (as defined by Section 7701(a)(30) of the U.S. Internal Revenue Code of 1986, as amended), and hereby represents that it has satisfied itself as to the full observance of the Laws of its jurisdiction in connection with its
purchase of the Shares including (a) the legal requirements within its jurisdiction for the purchase of the Shares, (b) any foreign exchange restrictions applicable to such purchase, (c) any governmental or other consents that may
need to be obtained, and (d) the income Tax and other Tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale, or transfer of the Shares. 

3.8    Governmental Review. GSK understands that no U.S. federal or state agency or any other Governmental
Authority has passed upon or made any recommendation or endorsement of the Shares or an investment therein. 
  

	Section	 4. CERTAIN COVENANTS 

4.1    Definitive Collaboration Agreement. Immediately following the Execution Date, Vir and GSK shall
commence negotiations with the intent to enter into the Definitive Collaboration Agreement. Vir and GSK shall use their respective best efforts to negotiate diligently and agree upon final terms for the Definitive Collaboration Agreement as promptly
as practicable following the Execution Date and in no event later than the later of (x) the Antitrust Clearance Date and (y) forty-five (45) days following the Execution Date (or such longer period as Vir and GSK may mutually agree in
writing) (the “Negotiation Period”). For the avoidance of doubt, entry into the Definitive Collaboration Agreement is not a condition to the effectiveness of this Agreement or the Preliminary Collaboration Agreement. If all
conditions set forth in Section 7.1 and Section 7.2 of this Agreement have been satisfied or waived, but the Definitive Collaboration Agreement has not been finalized and executed, the Closing
shall occur in accordance with the terms hereof and the Preliminary Collaboration Agreement, which is binding and governs the parties’ collaboration relationship, shall continue in full force and effect and Vir and GSK shall continue to
negotiate or otherwise finalize the Definitive Collaboration Agreement in accordance with Appendix E of the Preliminary Collaboration Agreement. 

4.2    Execution of Definitive Collaboration Agreement. Each of Vir and GSK shall duly execute and deliver
the Definitive Collaboration Agreement, on final terms as are (a) mutually agreed by Vir and GSK within the Negotiation Period, or (b) in the absence of such mutual agreement, determined in accordance with Appendix E of the Preliminary
Collaboration Agreement. 
 4.3    Preliminary Collaboration Agreement. Upon execution by the parties
thereto, the Preliminary Collaboration Agreement shall be a fully integrated and binding agreement and in full force and effect, subject only to the satisfaction of the conditions set forth therein. Neither party, nor any of their respective
Affiliates shall seek to assert that the Preliminary Collaboration Agreement or any term thereof is unenforceable for vagueness, or for not having sufficiently clear or defined terms, for failure of consideration or because it lacks any essential
term for enforcement 

  
 10 

 
and each of Vir and GSK, on behalf of themselves and their Affiliates, hereby waive any right to make such an assertion. To the extent that any material term has not been included in the
Preliminary Collaboration Agreement, Vir and GSK agree that such term (or terms) will be provided through the process set forth in Appendix E of the Preliminary Collaboration Agreement and will be binding and enforceable as if it had been included
in the Preliminary Collaboration Agreement. 
  

	Section	 5. STANDSTILL AGREEMENT 

5.1    Prior to the one-year anniversary of the Effective Date (the
“Standstill Period”), GSK and its Affiliates will not, directly or indirectly, except as expressly approved or invited by Vir or otherwise expressly permitted pursuant to this Section 5. 

(a)    effect or seek, offer or propose (whether publicly or otherwise) to effect, or cause or participate,
directly or indirectly (including through any other Person), in, (i) any acquisition of any securities (or beneficial ownership thereof) or material assets of Vir, (ii) any tender or exchange offer, merger, or other business combination
involving Vir, (iii) any recapitalization, restructuring, liquidation, dissolution or other extraordinary transaction with respect to Vir, or (iv) any “solicitation” of “proxies” (as such terms are used in
the proxy rules of the SEC) or consents to vote any voting securities of Vir; 
 (b)    form, join or in any way
participate in a “group” (as defined under the Exchange Act) with respect to any securities of Vir; 

(c)    otherwise act, alone or in concert with others, to seek to control or influence the management, Board or
policies of Vir (other than such policies as may be within the scope of the Preliminary Collaboration Agreement or the Definitive Collaboration Agreement); 

(d)    take any action that would reasonably be expected to require Vir to make a public announcement regarding any
of the types of matters set forth in clause (a) above; or 
 (e)    enter into any discussions or
arrangements with any Person with respect to any of the foregoing. 
 5.2    GSK also agrees during the
Standstill Period not to request Vir (or its representatives), directly or indirectly, amend or waive any provision of this Section 5 other than by means of a confidential communication to the Vir Chairman of the
Board or Chief Executive Officer. 
 5.3    GSK represents and warrants that, as of the Execution Date, neither
GSK nor any of its Affiliates owns, of record or beneficially, any voting securities of Vir, or any securities convertible into or exercisable for any voting securities of Vir. 

5.4    Notwithstanding the provisions set forth in Sections 5.1 and 5.2 (the “Standstill
Provisions”), GSK shall immediately, and without any other action by Vir, be released from its obligations under the Standstill Provisions if: (a) Vir executes, or publicly announces its intention to execute, a definitive agreement
with a third party providing for an acquisition (by way of merger, tender offer or otherwise), of more than 50% of Vir’s 

  
 11 

 
outstanding Common Stock or all or substantially all of Vir’s assets, (b) any person or “group” (as defined under the Exchange Act) commences a tender offer or makes an
offer or proposal which is made public seeking to acquire beneficial ownership of more than 50% of Vir’s outstanding Common Stock (with any acquisition described in clauses (a) and (b) referred to as a “Change of
Control Transaction”), (c) Vir waives any standstill or similar provision in any other agreement between Vir and a third party for the explicit purpose of allowing the third party to pursue or engage in any Change of Control
Transaction, or (d) Vir publicly announces the commencement of a formal process to solicit proposals for a potential business combination transaction. None of (i) the ownership or purchase by an employee benefit plan of GSK or GSK’s
Affiliates in any diversified index, mutual or pension fund managed by an independent advisor, which fund in-turn holds, directly or indirectly, securities of Vir, (ii) the acquisition of the equity
securities of an entity that owns such securities prior to such acquisition so long as such acquisition is not consummated for the purpose of circumventing this Section 5 or (iii) transfers or resales of the Shares by
GSK to any other person in compliance with Section 6, will be deemed to be a breach of GSK’s standstill obligations under this Section 5. 

 

	Section	 6. TRANSFER, RESALE, LEGENDS, REGISTRATION
RIGHTS 

 6.1    Transfer or Resale. GSK understands that: 

(a)    the Shares have not been and are not being registered under the Securities Act or any applicable state
securities Laws and, consequently, GSK may have to bear the risk of owning the Shares for an indefinite period of time because the Shares may not be transferred unless (i) the resale of the Shares is registered pursuant to an effective
registration statement under the Securities Act; (ii) GSK has delivered to Vir an opinion of counsel (in form, substance and scope customary for opinions of counsel in comparable transactions) to the effect that the Shares to be sold or
transferred may be sold or transferred pursuant to an exemption from such registration; or (iii) the Shares are sold or transferred pursuant to Rule 144 under the Securities Act (“Rule 144”); and 

(b)    any sale of the Shares made in reliance on Rule 144 may be made only in accordance with the terms of Rule
144 and, if Rule 144 is not applicable, any resale of the Shares under circumstances in which the seller (or the Person through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the Securities Act) may require
compliance with some other exemption under the Securities Act or the rules and regulations of the SEC thereunder. 

6.2    Lock-Up. GSK agrees that it will hold and will not sell any
of the Shares (or otherwise make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale of the Shares) until the
one-year anniversary of the Effective Date. Notwithstanding the foregoing, this Section 6.2 will not preclude (i) distributions of Shares to general or limited partners, members,
shareholders, Affiliates or wholly owned subsidiaries of GSK or any investment fund or other entity controlled or managed by GSK; provided, in each case, that following any such transfer such Shares will remain subject to the provisions of
this Section 6.2; or (ii) transfers pursuant to a bona fide third party tender offer for all outstanding shares of Common Stock, merger, consolidation or other similar transaction made to all holders of
Vir’s securities involving a change of control of Vir (including the entering 

  
 12 

 
into any lock-up, voting or similar agreement pursuant to which GSK may agree to transfer, sell, tender or otherwise dispose of Shares or other such
securities in connection with such transaction, or vote any Shares or other such securities in favor of any such transaction); provided that in the event that such tender offer, merger, consolidation or other such transaction is not
completed, the Shares shall remain subject to the provisions of this Section 6.2. 

6.3    Legends. GSK understands the Shares will bear restrictive legends in substantially the following form
(and a stop-transfer order may be placed against transfer of the Shares): 
 THE SHARES HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES
ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER SUCH ACT OR APPLICABLE STATE
SECURITIES LAWS OR A CERTIFICATE AND/OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. 
 THE
SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THESE SECURITIES IS SUBJECT TO THE TERMS AND CONDITIONS OF A STOCK PURCHASE AGREEMENT DATED APRIL 5, 2020 BETWEEN VIR BIOTECHNOLOGY, INC. AND GLAXO GROUP LIMITED. 

If such Shares may be transferred pursuant to Section 6.2 (excluding transfers pursuant to
Section 6.2(i)), GSK may request that Vir remove, and Vir agrees to authorize and instruct (including by causing any required legal opinion to be provided) the removal of any legend from the Shares, if permitted by
applicable securities Law, within two (2) Business Days of any such request; provided, however, that each party will be responsible for any fees it incurs in connection with such request and removal. 

6.4    Registration Rights. If, following the one year anniversary of the Effective Date, GSK proposes to
publicly resell the Shares pursuant to Rule 144 and GSK in good faith believes it will be unable to sell all of the Shares proposed to be sold by it pursuant to Rule 144 without volume or manner-of-sale restrictions, GSK shall notify Vir and Vir shall file as promptly as practicable a secondary only registration statement on Form S-3 (or any successor
form to Form S-3) promulgated under the Securities Act (which, if Vir is then a “well-known seasoned issuer” (as defined in Rule 405 under the Securities Act), shall be filed pursuant to General
Instruction I.D of Form S-3 (an “Automatic Shelf Registration Statement”)), registering the resale of such Shares (the “Registrable Securities”) (or, in the
event that Form S-3 is not available for the registration of the resale of the Registrable Securities, another appropriate form reasonably acceptable to GSK) by GSK (the “Registration
Statement”). Vir shall use commercially reasonable efforts (a) if the Registration Statement is not an Automatic Shelf Registration Statement, to cause the Registration Statement to become effective as promptly as
practicable; (b) to cause the Registration Statement to remain effective until the earlier of (i) the date on which GSK has disposed of all of the Registrable Securities and (ii) Rule 144 is available for the disposition of all
Registrable Securities without volume or manner-of-sale restrictions; (c) to undertake any additional actions reasonably necessary to maintain the availability of,
and to facilitate the disposition by GSK of the Registrable Securities pursuant to, the Registration Statement; and (d) to obtain any required consent under 

  
 13 

 
Vir’s Amended and Restated Investors’ Rights Agreement, dated as of November 19, 2017, by and among Vir and the investors party thereto or any other agreement to which Vir is a
party related to the filing of the Registration Statement. GSK agrees to cooperate with Vir as reasonably requested by Vir in connection with the preparation and filing of the Registration Statement, including furnishing to Vir such information
regarding itself, the shares of Common Stock held by it and the intended method of disposition of the Registrable Securities as shall be reasonably required to effect the registration of such Registrable Securities. Vir shall bear all expenses
incurred in connection with the performance of its obligations under this Section 6.4; provided, however, that Vir shall have no obligation to pay for any commissions or transfer taxes of GSK. Vir’s obligations
under this Section 6.4 shall also apply to any shares in the capital of Vir issued or issuable with respect to the Registrable Securities as a result of any share split, share dividend, recapitalization, exchange or similar
event. 
  

	Section	 7. CONDITIONS TO CLOSING 

7.1    Conditions to Obligations of Vir. Vir’s obligation to complete the purchase and sale of the
Shares and deliver the Shares to GSK is subject to the fulfillment or waiver of the following conditions at or prior to the Closing: 

(a)    Receipt of Funds. Vir will have received immediately available funds in the full amount of the
Purchase Price for the Shares being purchased hereunder. 
 (b)    Representations and Warranties. The
representations and warranties made by GSK in Section 3 will be true and correct in all material respects as of the Closing Date, except to the extent such representations and warranties are made as of another date, in
which case such representations and warranties will be true and correct in all material respects as of such other date. 

(c)    Covenants. All covenants and agreements contained in this Agreement to be performed or complied with
by GSK on or prior to the Closing Date shall have been performed or complied with in all material respects. 

(d)    Absence of Litigation. No proceeding challenging this Agreement or the transactions contemplated
hereby, or seeking to prohibit, alter, prevent or materially delay the Closing, will have been instituted or be pending before any Governmental Authority. 

(e)    No Governmental Prohibition; HSR Clearance. The sale of the Shares by Vir and the purchase of the
Shares by GSK will not be prohibited by any applicable Law at the time of the Closing. Each of the HSR Conditions shall have been satisfied. 

(f)    Preliminary Collaboration Agreement. GSK and Vir shall have duly executed and delivered the
Preliminary Collaboration Agreement and such agreement (or as it may be succeeded by the Definitive Collaboration Agreement) shall be in full force and effect. 

(g)    Closing Deliverables. All closing deliverables as required under
Section 1.3(b)(ii) shall have been delivered by GSK to Vir. 

  
 14 

 7.2    Conditions to GSK’s Obligations at
the Closing. GSK’s obligation to complete the purchase and sale of the Shares is subject to the fulfillment or waiver of the following conditions at or prior to the Closing: 

(a)    Representations and Warranties. The representations and warranties made by Vir in
Section 2 will be true and correct in all material respects as of the Closing Date, except to the extent such representations and warranties are made as of another date, in which case such representations and warranties
will be true and correct in all material respects as of such other date. 
 (b)    Covenants. All
covenants and agreements contained in this Agreement to be performed or complied with by Vir on or prior to the Closing Date shall have been performed or complied with in all material respects. 

(c)    Transfer Agent Instructions. Vir will have delivered to its transfer agent irrevocable written
instructions to issue the Shares to GSK in a form and substance acceptable to such transfer agent. 

(d)    Nasdaq Qualification. Nasdaq shall have raised no objection to the consummation of the transactions
contemplated by this Agreement in the absence of stockholder approval of such transactions. 
 (e)    Absence
of Litigation. No proceeding challenging this Agreement or the transactions contemplated hereby, or seeking to prohibit, alter, prevent or materially delay the Closing, will have been instituted or be pending before any Governmental Authority.

 (f)    Preliminary Collaboration Agreement. GSK and Vir shall have duly executed and delivered the
Preliminary Collaboration Agreement and such agreement (or as it may be succeeded by the Definitive Collaboration Agreement) shall be in full force and effect. 

(g)    No Governmental Prohibition; HSR Clearance. The sale of the Shares by Vir, and the purchase of the
Shares by GSK will not be prohibited by any applicable Law at the time of the Closing. Each of the HSR Conditions shall have been satisfied. 

(h)    Closing Deliverables. All closing deliverables as required under
Section 1.3(b)(i) shall have been delivered by Vir to GSK. 
  

	Section	 8. INDEMNIFICATION 

8.1    Indemnification by Vir. Vir shall indemnify and hold harmless GSK and its Affiliates, and the
directors, officers, employees and other agents and representatives of GSK and its Affiliates, from and against any and all liabilities, judgments, claims, settlements, losses, damages, fees, Liens, Taxes, penalties, obligations and expenses
(including reasonable attorney’s fees and expenses and costs and expenses of investigation) (collectively, “Losses”) incurred or suffered, directly or indirectly, by any such Person arising from, by reason of or in
connection with: (i) any breach or inaccuracy of any representation or warranty of Vir contained in this Agreement or any certificate delivered hereunder; and (ii) the non-fulfillment or breach by
Vir of any agreements or obligations under this Agreement. 

  
 15 

 8.2    Indemnification by GSK. GSK shall indemnify and
hold harmless Vir and its Affiliates, and the directors, officers, employees and other agents and representatives of Vir and its Affiliates, from and against any and all Losses incurred or suffered, directly or indirectly, by any such Person arising
from, by reason of or in connection with: (i) any breach or inaccuracy of any representation or warranty of GSK contained in this Agreement or any certificate delivered hereunder; and (ii) the
non-fulfillment or breach by GSK of any agreements or obligations under this Agreement. 

8.3    Calculation of Losses. Any indemnity payment hereunder shall be treated as an adjustment to the
Purchase Price to the extent permitted by applicable Law. Where the receipt of any such payment is treated for Tax purposes in a manner other than as an adjustment to the Purchase Price, the amount of the payment shall be adjusted to take account of
any net Tax cost actually incurred, or benefit actually enjoyed, by the Indemnified Party in respect thereof. 

8.4    Certain Procedures for Indemnification. 

(a)    If any Person entitled to indemnification under this Agreement (an “Indemnified
Party”) asserts a claim for indemnification, or receives notice of the assertion of any claim or of the commencement of any action by any Person not a party to this Agreement against such Indemnified Party, for which a party to this
Agreement is required to provide indemnification under this Section 8 (an “Indemnifying Party”), the Indemnified Party shall promptly notify the Indemnifying Party in writing of the claim or the
commencement of that action; provided, however, that the failure to so notify the Indemnifying Party shall not relieve the Indemnifying Party from any liability which it may have to the Indemnified Party, except to the extent that such
failure materially prejudices the Indemnifying Party’s ability to defend such action. 
 (b)    With respect
to third party claims for which indemnification is claimed hereunder, (i) the Indemnifying Party shall be entitled to participate in the defense of any such claim, and (ii) if, in the reasonable judgment of the Indemnified Party, such
claim can properly be resolved by money damages alone and the Indemnifying Party has the financial resources to pay such damages, and the Indemnifying Party admits that this indemnity fully covers the claim or litigation, then the Indemnifying Party
shall be entitled (y) to direct the defense of any claim at its sole cost and expense, but such defense shall be conducted by legal counsel reasonably satisfactory to the Indemnified Party, and (z) to settle and compromise any such claim
or action for money damages alone; provided, however, that if the Indemnified Party has elected to be represented by separate counsel pursuant to the proviso below, or if such settlement or compromise does not include an unconditional
release of the Indemnified Party for any liability arising out of such claim or action, such settlement or compromise shall be effected only with the written consent of the Indemnified Party. After notice from the Indemnifying Party to the
Indemnified Party of its election to assume the defense of such claim or action, the Indemnifying Party shall not be liable to the Indemnified Party under this Section 8.4 for any legal or other expenses subsequently
incurred by the Indemnified Party in connection with the defense thereof other than reasonable costs of investigation or of assistance as contemplated by this Section 8.4; provided, however, that if, in the
opinion of the Indemnified Party, it is advisable for the Indemnified Party to be represented by separate counsel due to actual or potential conflicts of interest, the Indemnified Party shall have the right to employ counsel to represent it and in
that event the fees and expenses of such separate counsel shall be paid by the Indemnifying Party; provided further, that in no event 

  
 16 

 
shall the Indemnifying Party be responsible for the fees of more than one counsel to the Indemnified Party. The Indemnified Party and the Indemnifying Party shall each render to each other such
assistance as may reasonably be requested in order to ensure the proper and adequate defense of any such claim or proceeding. 

8.5    Survival; Expiration. 

(a)    Notwithstanding any investigation made by or on behalf of Vir or GSK prior to, on or after the Closing Date,
the representations and warranties contained in this Agreement (including the exhibits and schedules hereto) and any certificate delivered hereunder shall survive the Closing and shall terminate on the second anniversary of the Closing Date. 

(b)    The covenants of the parties hereto shall survive until fully performed and discharged, unless otherwise
expressly provided herein. 
 (c)    Any right of indemnification or reimbursement pursuant to this
Section 8 with respect to a claimed breach, inaccuracy or non-fulfillment of any representation, warranty, agreement or obligation shall expire on the applicable date of termination
of the representation, warranty or covenant claimed to be breached (the “Expiration Date”), unless on or prior to the applicable Expiration Date, the Indemnifying Party has received written notice from the Indemnified Party
of such breach, inaccuracy or non-fulfillment from the Indemnified Party or is based on fraud or intentional or willful breach of the Indemnifying Party, in which case the Indemnified Party may continue to
pursue its right of indemnification or reimbursement hereunder beyond the Expiration Date of the applicable representation, warranty, agreement or obligation. For the avoidance of doubt no claims based on fraud or intentional or willful breach will
be subject to any of the limitations set forth in this Section 8.5. 
  

	Section	 9. DISPUTE RESOLUTION 

9.1    Any dispute arising out of or relating to the Agreement, or the breach, termination or validity thereof (a
“Dispute”), shall be finally resolved pursuant to the following provision: 
 (a)    In
the event a Dispute arises, the parties agree that they shall attempt in good faith to resolve the Dispute by negotiation between GSK’s Senior Vice President, Global Corporate Development and Vir’s Chief Executive Officer (or their
respective designee with power and authority to resolve such dispute) (such individuals, the “Senior Executives”). Either party may refer a Dispute to the Senior Executives by serving notice that a Dispute has arisen and
demand that negotiations commence. If the parties are unable for any reason to resolve a Dispute within thirty (30) days of service of the notice, either party shall have the right to refer the Dispute for mediation as set forth in
Section 9.1(b). 
 (b)    The parties agree that they shall try in good faith to
resolve the Dispute by referring it for confidential mediation under the CPR Mediation Procedure in effect at the start of mediation, before resorting to arbitration. If the parties cannot agree on a mediator within
twenty-one (21) days after the Dispute was referred to mediation, the mediator shall, upon request by either party, be appointed by CPR pursuant to CPR Mediation Procedure. The cost of mediator shall be
borne equally by the parties. Any Dispute not resolved within forty-five (45) days (or within such other time period as may be agreed to by parties in writing) after appointment of the mediator shall be finally resolved by arbitration pursuant
to this Section 9. 

  
 17 

 (c)    The arbitration shall be administered by the International
Centre for Dispute Resolution (“ICDR”) in accordance with its International Arbitration Rules, except as those rules may be modified herein or by mutual agreement of the parties. Any disputes concerning the propriety of the
commencement of the arbitration or the scope or applicability of this agreement to arbitrate shall be finally settled by the arbitrators. In any such arbitration, the number of arbitrators shall be three. Each party shall appoint one arbitrator
within fourteen (14) days after submission of the Answer to the Notice of Arbitration, and the two party-appointed arbitrators shall appoint a third arbitrator, who shall serve as chair of the tribunal, within
twenty-one (21) days of the appointment of the later-appointed arbitrator. If any of the arbitrators are not appointed within the time prescribed above, then the ICDR shall appoint the arbitrator(s) in
accordance with its International Arbitration Rules. 
 (d)    The seat of the arbitration shall be New York
City, New York, and the language of the arbitration shall be English. The parties submit to the non-exclusive jurisdiction of the state and federal courts located in New York County in the state of New
York for the limited purpose of enforcing this Agreement to arbitrate and any action for preliminary relief. The arbitration award shall be final and binding and the parties undertake to carry out any award without delay. Judgment upon the award may
be entered by any court having jurisdiction thereof or having jurisdiction over the relevant party and its assets. 

(e)    GSK and Vir agree that the existence of the arbitration, any
non-public information provided in the arbitration, all submissions made in the arbitration, any rulings and the award shall be kept confidential except as may be necessary to prepare for or conduct the
arbitration hearing on the merits, or except as may be necessary in connection with a court application for a preliminary remedy, a judicial challenge to the award or its enforcement, or unless otherwise required by Law or judicial decision. 

(f)    For the avoidance of doubt, any disputes with respect to the terms of the Preliminary Collaboration
Agreement or the Definitive Collaboration Agreement shall be resolved in accordance with the dispute resolution provisions therein, including the provisions of Section 17 and Appendices E and F of the Preliminary Collaboration Agreement, and
not the provisions of this Section 9. For clarity, any dispute with respect to the terms of Sections 4.1, 4.2 or 4.3 hereof, including a breach thereof, shall not be considered a dispute with respect to
the terms of the Preliminary Collaboration Agreement or the Definitive Collaboration Agreement and shall be subject to the related provisions of this Agreement, including the terms of this Section 9.1 and
Section 8, Section 11.1 and Section 11.13 hereof. 
  

	Section	 10. TERMINATION 

10.1    Ability to Terminate. This Agreement may be terminated prior to the Closing: 

(a)    at any time by mutual written consent of Vir and GSK; 

(b)    by Vir, upon thirty (30) days’ written notice to GSK, so long as Vir is not then in breach of its
representations, warranties, covenants or agreements under this Agreement 

  
 18 

 
such that any of the conditions set forth in Section 7.1, as applicable, could not be satisfied by the Termination Date, (i) upon a breach of any covenant or
agreement on the part of GSK set forth in this Agreement that has not been cured within such 30-day notice period, or (ii) if any representation or warranty of GSK shall have been or become untrue, in
each case such that any of the conditions set forth in Section 7.1 could not be satisfied by the Termination Date; 

(c)    by GSK, upon thirty (30) days’ written notice to Vir, so long as GSK is not then in breach of its
representations, warranties, covenants or agreements under this Agreement such that any of the conditions set forth in Section 7.2 of this Agreement, as applicable, could not be satisfied by the Termination Date,
(i) upon a breach of any covenant or agreement on the part of Vir set forth in this Agreement that has not been cured within such 30-day notice period, or (ii) if any representation or warranty of
Vir shall have been or become untrue, in each case such that any of the conditions set forth in Section 7.2 of this Agreement could not be satisfied by the Termination Date; 

(d)    by either Vir or GSK, upon written notice to the other, if the Antitrust Clearance Date has not occurred on
or before July 10, 2020 (the “Termination Date”). In such event, neither party shall have any further obligations under this Agreement. 

10.2    Effect of Termination. In the event of the termination of this Agreement pursuant to
Section 10, (a) this Agreement (except for this Section 10.2, and Section 8, Section 9, Section 11.1 and Sections
11.3 through 11.14 and any definitions set forth in this Agreement and used in such Sections) shall forthwith become void and have no effect, without any liability on the part of any party hereto or its Affiliates, and (b) all
filings, applications and other submissions made pursuant to this Agreement, to the extent practicable, shall be withdrawn from the agency or other Person to which they were made or appropriately amended to reflect the termination of the
transactions contemplated hereby; provided, however, that nothing contained in this Section 10.2 shall relieve any party from liability for fraud or any intentional or willful breach of this Agreement. 

 

	Section	 11. GOVERNING LAW; MISCELLANEOUS 

11.1    Governing Law. This Agreement will be governed by and interpreted in accordance with the laws of the
State of Delaware without regard to the principles of conflict of laws that would require the application of the substantive Laws of another jurisdiction. 

11.2    HSR Clearance; Market Listing. 

(a)    Subject to the terms and conditions of this Agreement, each of GSK and Vir will use its reasonable best
efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary, proper or advisable under applicable Law to consummate the acquisition of the Shares, the transactions contemplated by the Preliminary
Collaboration Agreement and the negotiation and entry into the Definitive Collaboration Agreement, as soon as practicable after the date hereof, including taking all steps as may be necessary, subject to the limitations in this
Section 11.2, to obtain all applicable waiting period expirations or terminations, consents, clearances, waivers, licenses, registrations, permits, authorizations, orders and approvals. In furtherance and not in limitation
of the foregoing, each of GSK and Vir agrees to (i) 

  
 19 

 
file or cause to be filed with the FTC and the DOJ any notifications required to be filed under the HSR Act no later than April 10, 2020, or if the DOJ and FTC are not accepting filings on
such day, on the first day thereafter that filings are accepted (unless otherwise mutually agreed to by the parties), and (ii) use commercially reasonable efforts to obtain as promptly as practicable the termination or expiration of any waiting
period under the HSR Act, including by filing as soon as practicable and advisable any supplemental or additional information which may reasonably be requested by the FTC or the DOJ or any other Governmental Authority in connection with applicable
Antitrust Law; provided that the obligations in clause (ii) shall not require Vir or GSK or any of its Affiliates to (x) sell, divest (including through a license or a reversion of licensed or assigned rights), hold separate,
transfer or dispose of any assets, operations, rights, product lines, businesses or interest therein of Vir or GSK or any of their Affiliates (or consent to any of the foregoing actions); or (y) litigate or otherwise formally oppose any
determination (whether judicial or administrative in nature) by a Governmental Authority seeking to impose any of the restrictions referenced in clause (x). GSK shall be responsible for the payment of all filing fees payable under the HSR Act
and any other applicable Antitrust Law. 
 (b)    Each of GSK and Vir shall use commercially reasonable efforts
to provide or cause to be provided promptly all assistance and cooperation to allow GSK and Vir to prepare and submit any filings or submissions under the HSR Act, including providing to GSK and Vir, as applicable, any information that it may
require for the purpose of any filing, notification, application or request for further information made in respect of any such filing. 

(c)    Each of GSK and Vir shall, in connection with the transactions contemplated hereby, and the obtaining of all
waiting period expirations or terminations, consents, clearances, waivers, licenses, orders, registrations, approvals, permits and authorizations under the HSR Act or any other Antitrust Law, with respect to actions taken on or after the date of
this Agreement, without limitation: (i) promptly notify the other of, and if in writing, furnish the other with copies of (or, in the case of oral communications, advise the other of) any material communications from or with any Governmental
Authority, including the FTC and the DOJ, with respect to the agreement, (ii) cooperate in all respects and consult with each other in connection with any filing or submission and in connection with any investigation or other inquiry,
(iii) permit the other to review and discuss in advance, and consider in good faith the view of the other in connection with, any proposed written or oral communication with any Governmental Authority, (iv) not participate in any
substantive meeting or have any substantive communication with any Governmental Authority unless it has given the other party a reasonable opportunity to consult with it in advance and, to the extent permitted by such Governmental Authority, gives
the other the opportunity to attend and participate therein, (v) furnish the other party’s outside legal counsel with copies of all supplemental filings and substantive communications between it and any such Governmental Authority with
respect to the Agreement; provided that neither party will be required to provide the other party with its board of directors or internal committee materials; and any materials subject to this Section 11.2(c) may be
restricted to outside counsel and may be redacted or withheld as necessary (A) to comply with contractual arrangements, (B) to address good faith legal privilege or confidentiality concerns and (C) to comply with applicable Law,
(vi) furnish the other party’s outside legal counsel with such necessary information and reasonable assistance as the other party’s outside legal counsel may reasonably request in connection with its preparation of necessary
submissions of information to any such Governmental Authority, and (vii) use commercially reasonable efforts to respond as soon as practicable to reasonable requests 

  
 20 

 
for information by any Governmental Authority. Neither GSK nor Vir shall commit to or agree with any Governmental Authority to stay, toll, or extend any applicable waiting period under the HSR
Act or other applicable Antitrust Law, or pull and refile under the HSR Act, without the prior written consent of the other. 

(d)    From the Execution Date through the Closing, Vir shall use commercially reasonable efforts to
(a) maintain the listing and trading of the Common Stock on Nasdaq and (b) effect the listing of the Shares on Nasdaq. 

11.3    Counterparts; Electronic Signatures. This Agreement may be executed and delivered (including by
facsimile transmission or PDF or any other electronically transmitted signatures) in two counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

11.4    Headings. The headings of this Agreement are for convenience of reference only, are not part of this
Agreement and do not affect its interpretation. 
 11.5    Rules of Construction. 

(a)    For purposes of this Agreement, whenever the context requires: the singular number shall include the plural,
and vice versa; the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include the masculine and feminine genders. 

(b)    As used in this Agreement, (i) the words “include” and “including,” and variations
thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words “without limitation”, (ii) the words “hereby,” “herein,” “hereunder” and “hereto” shall
be deemed to refer to this Agreement in its entirety and not to any specific section of this Agreement and (iii) “or” has the inclusive meaning represented by the phrase “and/or”. 

(c)    Except as otherwise indicated, all references in this Agreement to “Sections” and
“Appendices” are intended to refer to Sections of this Agreement, as appropriate, and Appendices to this Agreement. 

(d)    As used in this Agreement, the term “days” means calendar days unless otherwise specified. When
calculating the period of time before which, within which or following which any act is to be done or step taken pursuant to this Agreement, the date that is the reference date in calculating such period shall be excluded. If the last day of such
period is a non-Business Day, the period in question shall end on the next succeeding Business Day. 

(e)    Unless otherwise indicated, all monetary amounts herein are in United States dollars. 

11.6    Severability. If any provision of this Agreement should be held invalid, illegal or unenforceable in
any jurisdiction, the parties will negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the parties and all other provisions hereof will remain in full force and effect in such
jurisdiction and will be liberally construed in order to carry out the intentions of the parties hereto as nearly as may be possible. Such invalidity, illegality or unenforceability will not affect the validity, legality or enforceability of such
provision in any other jurisdiction. 

  
 21 

 11.7    Entire Agreement; Amendments. This Agreement, the
Preliminary Collaboration Agreement and, once entered into, the Definitive Collaboration Agreement (including any schedules, appendices and exhibits hereto or thereto and any certificates delivered hereunder) constitute the entire agreement between
the parties hereto with respect to the subject matter hereof and thereof. There are no restrictions, promises, warranties or undertakings, other than those set forth or referred to herein or therein. This Agreement supersedes all prior agreements
and understandings between the parties hereto with respect to the subject matter hereof. No provision of this Agreement may be waived or amended other than by an instrument in writing signed by the party to be charged with enforcement. Any amendment
or waiver effected in accordance with this Section 11.7 shall be binding upon GSK and Vir. 

11.8    Notices. All notices required or permitted hereunder will be in writing and will be deemed
effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed email if sent during normal business hours of the recipient, if not, then on the next Business Day, or (c) one Business Day after
deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. The addresses for such communications are: 

 

			
	If to Vir, addressed to:	  	Vir Biotechnology, Inc.
		  	499 Illinois Street, Suite 500
		  	San Francisco, CA 94158
		  	Attention: 
		  	E-mail:
		
	and	  	Vir Biotechnology, Inc.
		  	499 Illinois Street, Suite 500
		  	San Francisco, CA 94158
		  	Attention: 
		  	E-mail:
		
	with a copy to:	  	Cooley LLP
		  	3175 Hanover Street
		  	Palo Alto, CA 94304-1130
		  	Attention:
		  	E-mail:
		
	If to GSK, addressed to:	  	Glaxo Group Limited
		
	with a copy to:	  	Covington & Burling LLP
		  	The New York Times Building
		  	320 Eighth Avenue
		  	New York, New York 10018
		  	Attention:
		  	E-mail:

  
 22 

 11.9    Successors and Assigns. This Agreement is binding
upon and inures to the benefit of the parties and their successors and assigns. Vir will not assign this Agreement or any rights or obligations hereunder without the prior written consent of GSK, and GSK will not assign this Agreement or any rights
or obligations hereunder without the prior written consent of Vir; provided, however, that GSK may assign this Agreement together with all of the Shares it then owns (subject to Section 6) to any wholly-owned
subsidiary and any such assignee may assign the Agreement together with all of the Shares it then owns (subject to Section 6) to GSK or any other subsidiary wholly-owned by GSK, in any such case, without such consent;
provided that the assignee agrees to assume GSK’s obligations under Section 6 of this Agreement. 

11.10    Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto, their
respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person. 

11.11    Further Assurances. Each party will do and perform, or cause to be done and performed, all such
further acts and things, and will execute and deliver all other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the
consummation of the transactions contemplated hereby. 
 11.12    No Strict Construction. The
language used in this Agreement is deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against a party. 

11.13    Equitable Relief. Vir recognizes that, if it fails to perform or discharge any of its obligations
under this Agreement, any remedy at Law may prove to be inadequate relief to GSK. Vir therefore agrees that GSK is entitled to seek temporary and permanent injunctive relief or specific performance in any such case. GSK also recognizes that, if it
fails to perform or discharge any of its obligations under this Agreement, any remedy at Law may prove to be inadequate relief to Vir. GSK therefore agrees that Vir is entitled to seek temporary and permanent injunctive relief or specific
performance in any such case. 
 11.14    Expenses. Vir and GSK are each liable for, and will pay, their
own expenses incurred in connection with the negotiation, preparation, execution and delivery of this Agreement, including attorneys’ and consultants’ fees and expenses.  

11.15    Public Disclosure. On or within one Business Day of the Execution Date, Vir and GSK shall issue a
joint press release in a form mutually agreed to by Vir and GSK. In addition, Vir shall file a Current Report on Form 8-K with the SEC within the time period required by such form and including such
disclosures as required by such form with respect to this Agreement and the transactions contemplated herein, such Current Report on Form 8-K to be in a form mutually agreed to by Vir and GSK. No other written
release, public announcement, disclosure or filing concerning the purchase of the Shares, this Agreement, the Preliminary Collaboration Agreement, the Definitive Collaboration Agreement or the transactions contemplated hereby or thereby shall

  
 23 

 
be issued, filed or furnished, as the case may be, by any party without the prior written consent of the other party (which consent shall not be unreasonably withheld, conditioned or delayed)
and, except as set forth in this Section 11.15, the parties agree to keep the terms of this Agreement, the Preliminary Collaboration Agreement and the Definitive Collaboration Agreement confidential. Notwithstanding the
foregoing, the parties acknowledge and agree that applicable Law or the requirements of a national securities exchange or another similar regulatory body may require either party to file or otherwise disclose a copy of this Agreement, the
Preliminary Collaboration Agreement or the Definitive Collaboration Agreement. The party required to make such filing or otherwise disclose shall notify the other party and shall provide the other party with at least three (3) days to request
redactions thereof prior to making such filing or disclosure. The disclosing party shall use commercially reasonable efforts to procure confidential treatment of such proposed redactions pursuant to the Securities Act and the Exchange Act, in each
case as amended, and the rules, regulations and guidelines promulgated thereunder, or any other applicable Law or the rules, regulations or guidelines promulgated hereunder; provided that the foregoing shall not prevent the party from making
such public disclosures as it must make to comply with applicable Law. 
 [Remainder of page intentionally left blank.] 

  
 24 

 IN WITNESS WHEREOF, GSK and Vir have
caused this Agreement to be duly executed as of the date first above written. 
  

			
	GLAXO GROUP LIMITED
		
	By:	 	 /s/ Victoria Whyte

	Name:	 	Victoria Whyte
	Its:	 	Company Secretary
	
	VIR BIOTECHNOLOGY, INC.
		
	By:	 	 /s/ George Scangos

	Name:	 	George Scangos
	Its:	 	President and Chief Executive Officer

  
 [Signature page to
Stock Purchase Agreement] 

 APPENDIX 1 

DEFINED TERMS 

“Affiliate” of an entity means any corporation, firm, partnership or other entity that directly or indirectly through one or more
intermediaries controls, is controlled by or is under common control with it. An entity will be deemed to control another entity if it (i) owns, directly or indirectly, at least 50% of the outstanding voting securities or capital stock (or such
lesser percentage that is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of such other entity, or has other comparable ownership interest with respect to any entity other than a corporation; or (ii) has
the power, whether pursuant to contract, ownership of securities or otherwise, to direct the management and policies of the entity. 

“Agreement” has the meaning set forth in the preamble. 

“Antitrust Clearance Date” has the meaning set forth in the definition of “Effective Date.” 

“Antitrust Law” means the HSR Act, the Sherman Antitrust Act, as amended, the Clayton Act, as amended, the Federal Trade Commission
Act, as amended, and any other applicable Law designed to prohibit, restrict or regulate actions or transactions having the purpose or effect of monopolization, restraint of trade or harm to competition. 

“Applicable Regulatory Authorities” has the meaning set forth in Section 2.12. 

“Automatic Shelf Registration Statement” has the meaning set forth in Section 6.4. 

“Board” means the board of directors of Vir. 

“Business Day” means a day Monday through Friday on which banks are generally open for business in the State of California, the State
of New York and London, England. 
 “Change of Control Transaction” has the meaning set forth in
Section 5.4. 
 “Closing” has the meaning set forth in Section 1.3(a). 

“Closing Date” means the date on which the Closing actually occurs. 

“Common Stock” means shares of Vir’s common stock, par value $0.0001 per share. 

“Company Trials” has the meaning set forth in Section 2.13. 

“CPR” means the International Institute for Conflict Prevention & Resolution (www.cpradr.org). 

“Cross-Receipt” has the meaning set forth in Section 1.3(b)(i)(A). 

“Definitive Collaboration Agreement” has the meaning set forth in the Recitals. 

“Dispute” has the meaning set forth in Section 9.1. 

 “DOJ” means the U.S. Department of Justice. 

“Effective Date” means the date that is the date on which: (a) the waiting period under the HSR Act shall have
expired or earlier been terminated; (b) no judicial or administrative proceeding opposing consummation of all or any part of this Agreement shall be pending; and (c) no Law, order or injunction (whether temporary, preliminary or permanent)
prohibiting consummation of the transactions contemplated by this Agreement or any material portion hereof shall be in effect (each of clauses (a) through (c), collectively, the “HSR Conditions,” and such
date on which all of the HSR Conditions have been met, the “Antitrust Clearance Date”), unless either party exercises its termination right under Section 10.1(d) at any time prior to
the Antitrust Clearance Date. 
 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations
of the SEC thereunder. 
 “Execution Date” has the meaning set forth in the preamble. 

“Expiration Date” has the meaning set forth in Section 8.5(c). 

“FDA” has the meaning set forth in Section 2.12. 

“Field” means the prevention, treatment and prophylaxis of diseases caused by coronaviruses (including SARS-COV-2 and any variants thereof) in humans, including the disease known as CoVID-19. 

“FTC” means the U.S. Federal Trade Commission. 

“GAAP” means generally accepted accounting principles in the United States of America. 

“Good Clinical Practices” means the legal, scientific and ethical standards for the performance of clinical research on medicinal
products involving humans, including as reflected in the regulations of the FDA at 21 C.F.R. parts 50, 54, 56, and 312. 
 “Good Laboratory
Practices” means the legal, scientific and ethical standards for the performance of nonclinical laboratory studies, including as set out in the regulations of the FDA at 21 C.F.R. part 58. 

“Governmental Authority” means any Federal, state, provincial, local, municipal, foreign or other governmental or quasi-governmental
authority, including any arbitrator and applicable securities exchanges, or any department, minister, agency, commission, commissioner, board, subdivision, bureau, agency, instrumentality, court or other tribunal of any of the foregoing. 

“GSK” has the meaning set forth in the preamble. 

“Health Care Laws” means Title XVIII of the Social Security Act, 42 U.S.C. §§ 1395-1395lll (the Medicare statute); Title XIX
of the Social Security Act, 42 U.S.C. §§ 1396-1396w-5 (the Medicaid statute); the Federal Anti-Kickback Statute, 42 U.S.C. § 1320a-7b(b); the civil False
Claims Act, 31 U.S.C. §§ 3729 et seq.; the criminal False Claims Act 42 U.S.C. 1320a-7b(a); any other criminal 

 
laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. Sections 286 and 287 and the health care fraud criminal provisions under the Health Insurance Portability and
Accountability Act of 1996, 42 U.S.C. §§ 1320d et seq., (“HIPAA”); the Civil Monetary Penalties Law, 42 U.S.C. §§ 1320a-7a; the Physician Payments Sunshine Act, 42
U.S.C. § 1320a-7h; the Exclusion Laws, 42 U.S.C. § 1320a-7; HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, 42
U.S.C. §§ 17921 et seq.; the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 301 et seq.; the Public Health Service Act, 42 U.S.C. §§ 201 et seq.; the regulations promulgated pursuant to such laws; and any similar
federal, state and local laws and regulations, each and all as may be amended from time to time. 
 “HIPAA” has the meaning set
forth in the definition of “Health Care Laws.” 
 “HSR Act” means the Hart-Scott-Rodino Antitrust Improvements Act of
1976, as amended. 
 “HSR Conditions” has the meaning set forth in the definition of “Effective Date.” 

“ICDR” has the meaning set forth in Section 9.1(c). 

“IEC” has the meaning set forth in Section 2.13. 

“Indemnified Party” has the meaning set forth in Section 8.4(a). 

“Indemnifying Party” has the meaning set forth in Section 8.4(a). 

“Intellectual Property” shall mean trademarks, trade names, trade dress, service marks, copyrights, and similar rights (including
registrations and applications to register or renew the registration of any of the foregoing), patents and patent applications, trade secrets, and any other similar intellectual property rights. 

“Intellectual Property License” shall mean any license, permit, authorization, approval, contract or consent granted, issued by or
with any Person relating to the use of Intellectual Property. 
 “IRB” has the meaning set forth in
Section 2.13. 
 “Law” means any federal, state, local or foreign constitution, treaty, law, statute,
ordinance, rule, regulation, interpretation, directive, policy, order, writ, decree, injunction, judgment, stay or restraining order of any Governmental Authority, the terms of any permit, and any other ruling or decision of, agreement with or by,
or any other requirement of, any Governmental Authority. 
 “Lien” means any lien (statutory or otherwise), claim, charge, option,
security interest, pledge, mortgage, restriction, financing statement or similar encumbrance of any kind or nature whatsoever (including any conditional sale or other title retention agreement and any lease having substantially the same effect as
any of the foregoing and any assignment or deposit arrangement in the nature of a security device). 
 “Losses” has the meaning set
forth in Section 8.1. 

 “Material Adverse Effect” means any change, effect or circumstance, individually or
in the aggregate, (a) that is reasonably likely to be materially adverse to the business, operations, assets or financial condition of Vir or GSK, as the case may be, taken as a whole, or (b) that materially impairs the ability of Vir or
GSK to perform its obligations pursuant to the transactions contemplated by this Agreement or the Preliminary Collaboration Agreement; provided however, that, none of the following (alone or when aggregated with any other effects), shall be
deemed to be a Material Adverse Effect, and none of the following (alone or when aggregated with any other effects), shall be taken into account for purposes of clause (a) above: (A) (1) general market, economic or political
conditions or (2) conditions (or any changes therein) in the industries in which Vir or GSK conducts business, in each case, including any acts of terrorism or war, weather conditions, global virus pandemics, epidemics or other force majeure
events, in the case of each of clauses (1) and (2), solely to the extent that such effects do not have and are not reasonably likely to have a material disproportionate impact on Vir or GSK, as the case may be; (B) this
Agreement, the Preliminary Collaboration Agreement and the transactions contemplated hereby and thereby; or (C) changes in the trading price or volume of the Common Stock or GlaxoSmithKline plc’s ordinary shares, in and of themselves. 

“Nasdaq” means The Nasdaq Global Select Market. 

“Negotiation Period” has the meaning set forth in Section 4.1. 

“Permits” has the meaning set forth in Section 2.10. 

“Person” means a human being, labor organization, partnership, firm, enterprise, association, joint venture, corporation, limited
liability company, cooperative, legal representative, foundation, society, political party, estate, trust, trustee, trustee in bankruptcy, receiver or any other organization or entity whatsoever, including any Governmental Authority. 

“Preferred Stock” means shares of Vir’s preferred stock, par value $0.0001 per share. 

“Preliminary Collaboration Agreement” has the meaning set forth in the Recitals. 

“Proprietary Rights” has the meaning set forth in Section 2.11(c). 

“Purchase Price” has the meaning set forth in Section 1.1. 

“Registrable Securities” has the meaning set forth in Section 6.4. 

“Registration Statement” has the meaning set forth in Section 6.4. 

“Regulatory Authorizations” has the meaning set forth in Section 2.12. 

“Rule 144” has the meaning set forth in Section 6.1(a). 

“SEC” means the United States Securities and Exchange Commission or any successor entity. 

“SEC Documents” has the meaning set forth in Section 2.5(a). 

 “Securities Act” means the Securities Act of 1933, as amended, and the rules and
regulations of the SEC thereunder. 
 “Senior Executives” has the meaning set forth in Section 9.1(a).

 “Shares” has the meaning set forth in Section 1.1. 

“Standstill Period” has the meaning set forth in Section 5.1. 

“Standstill Provisions” has the meaning set forth in Section 5.4. 

“Tax” means any federal, state, local, or foreign income, gross receipts, license, payroll, employment, excise, severance, stamp,
occupation, premium, windfall profits, environmental (including taxes under Section 59A of the Internal Revenue Code of 1986, as amended), customs duties, capital stock, franchise, profits, withholding, social security (or similar),
unemployment, disability, real property, personal property, sales, use, transfer, registration, value added, alternative or add-on minimum, estimated, or other tax of any kind whatsoever, including any
interest, penalty, or addition thereto, whether disputed or not. 
 “Termination Date” has the meaning set forth in
Section 10.1(d). 
 “Vir” has the meaning set forth in the preamble. 

“Vir Rights” has the meaning set forth in Section 2.11(c). 

 Appendix 2 

See attached.EX-10.56

 Exhibit 10.56 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. 
  

					
	CONFIDENTIAL	  		  	EXECUTION VERSION

 CLINICAL DEVELOPMENT 

AND MANUFACTURING AGREEMENT 

BETWEEN 
 BIOGEN INC. 

AND 
 VIR BIOTECHNOLOGY, INC. 

DATED May 22, 2020 
  

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
			
	ARTICLE 1	 	 DEFINITIONS
	  	 	1	 
			
	ARTICLE 2	 	 SCOPE
	  	 	7	 
			
	ARTICLE 3	 	 PAYMENTS
	  	 	13	 
			
	ARTICLE 4	 	 MANUFACTURING AND FILL FINISH
	  	 	16	 
			
	ARTICLE 5	 	 REGULATORY
	  	 	19	 
			
	ARTICLE 6	 	 CONFIDENTIALITY AND NON-USE
	  	 	21	 
			
	ARTICLE 7	 	 INTELLECTUAL PROPERTY
	  	 	23	 
			
	ARTICLE 8	 	 REPRESENTATIONS AND WARRANTIES
	  	 	25	 
			
	ARTICLE 9	 	 INDEMNIFICATION
	  	 	27	 
			
	ARTICLE 10	 	 LIMITATIONS OF LIABILITY
	  	 	28	 
			
	ARTICLE 11	 	 INSURANCE
	  	 	28	 
			
	ARTICLE 12	 	 TERM AND TERMINATION
	  	 	28	 
			
	ARTICLE 13	 	 NOTICE
	  	 	30	 
			
	ARTICLE 14	 	 MISCELLANEOUS
	  	 	30	 

  

			
	ATTACHMENT A-1, A-2, etc.	  	STATEMENTS OF WORK
		
	ATTACHMENT B	  	FORM OF CONFIDENTIAL DISCLOSURE AND LIMITED USE AGREEMENT
		
	ATTACHMENT C	  	ACCESS FEES
		
	ATTACHMENT D	  	MANUFACTURING REQUEST

  

  
 i 

 CLINICAL DEVELOPMENT AND MANUFACTURING AGREEMENT 

This Clinical Development and Manufacturing Agreement (“Agreement”) is made as of this 22nd day of May, 2020 (“Effective Date”), by and between Vir Biotechnology, Inc., a Delaware corporation, having a place of business at 499 Illinois Street, Suite 500, San Francisco, CA
94158 (“Vir”) and Biogen Inc., a Delaware corporation, having a place of business at 225 Binney Street, Cambridge, MA 02142 (“Biogen”). 

RECITALS 
 A. Biogen
develops, manufactures and commercializes its own and Third Party proprietary biopharmaceutical products and has facilities for and expertise in developing and manufacturing biologics, including proprietary cell line engineering and expression
technologies; 
 B. Vir develops, markets and sells drug products directed to the treatment of infectious diseases, including diseases caused
by the coronavirus known as SARS-CoV-2; 
 C. Vir wishes to
obtain, and Biogen wishes to provide, certain services relating to the development of certain biologic drug products; 
 D. Vir may wish to
obtain, and Biogen shall have the option, as further detailed in this Agreement, to provide certain manufacturing activities for clinical supply of certain biologic drug products; and 

E. Vir wishes to obtain, and Biogen wishes to provide, as further detailed in this Agreement, certain technology transfer and manufacturing
activities to enable Vir to obtain timely access to and production of commercial supply of certain biologic products for prevention and/or treatment of COVID-19 patients; 

Vir and Biogen desire to enter into this Agreement to provide the terms and conditions upon which Vir may engage Biogen to provide services as
further detailed in individual SOWs (as defined below). 
 THEREFORE, in consideration of the premises set forth above and the mutual
covenants, terms and conditions set forth below, the Parties agree as follows: 
 ARTICLE 1 

DEFINITIONS 
 The following terms have the
following meanings in this Agreement: 
 1.1 “Access Fees” has the meaning set forth in Section 3.1.3. 

1.2 “Advisory Forecast” has the meaning set forth in Section 4.1.3. 

1.3 “Affiliate(s)” means any person, firm, trust, partnership, corporation, company or other entity or combination thereof which directly or
indirectly: (i) controls a Party; (ii) is controlled by a Party; or (iii) is under common control with a Party. As used in this definition, the terms “control” and “controlled” will mean ownership of
fifty percent (50%) or more (including ownership by trusts with substantially the same beneficial interests) of the voting and equity rights of such person, firm, trust, partnership, corporation, company or other entity or combination thereof or the
power to direct the management of such person, firm, trust, corporation or other entity or combination thereof. 

 1.4 “Agreement” has the meaning set forth in the introductory paragraph, and includes all
its Attachments and other appendices (all of which are incorporated herein by reference) and any amendments to any of the foregoing made as provided herein or therein. 

1.5 “Annual Cap” has the meaning set forth in Section 4.1.4. 

1.6 “Applicable Laws” means, with respect to Vir, all laws, ordinances, rules and regulations, currently in effect or enacted or promulgated
during the Term, and as amended from time to time, of each jurisdiction in which Drug Substance or Drug Product is produced, marketed, distributed, used or sold; and with respect to Biogen, all laws, ordinances, rules and regulations, currently in
effect or enacted or promulgated during the Term, and as amended from time to time, of the jurisdiction in which Biogen performs Services; provided that cGMP shall not constitute Applicable Laws except to the extent expressly stated in the
applicable SOW. 
 1.7 “Attempted Batch(es)” has the meaning set forth in Section 1.8. 

1.8 “Batch” means a specific quantity of Drug Substance or Drug Product produced in accordance with a defined set of release criteria.
“Batches” includes (i) batches subject to the Binding Forecast set forth in Section 4.1.3; (ii) batches for which Manufacturing has actually commenced (“Attempted Batches”), and
(iii) batches produced in accordance with and meeting their applicable Specifications, including successful in-process testing and completing of applicable documentation (“Successful
Batches”). 
 1.9 “Baseline Yield” has the meaning set forth in Attachment C. 

1.10 “Batch Record” means a Manufacturing record for a Batch generated by Biogen concurrently with the production of a specific Batch such
that successive steps in such processes are documented. 
 1.11 “Binding Forecast” has the meaning set forth in
Section 4.1.3. 
 1.12 “Biogen” has the meaning set forth in the introductory paragraph, or any successor or
permitted assign. 
 1.13 “Biogen Defective Processing” has the meaning set forth in Section 4.3. 

1.14 “[***]” has the meaning as set forth [***]. 

1.15 “Biogen Indemnitees” has the meaning set forth in Section 9.2. 

1.16 “Biogen IP” has the meaning set forth in Section 7.1. 

1.17 “Biogen Process Invention” has the meaning set forth in Section 7.1. 

1.18 “[***]” means, [***]. 
 1.19 “Biogen
Proprietary Know-How” means [***]. 
 1.20 “Campaign” means a Batch or series of
Batches of the same Product that are produced in sequence using the same Manufacturing equipment (including the same bioreactor); provided that a change of equipment initiated by Biogen for reasons of equipment malfunction or maintenance, capacity
constraint, or other reasons other than a requirement or request of Vir will, for purposes of this definition, be considered to be a part of the same Campaign. 

  
 2 

 1.21 “Capital Costs” means (i) with respect to any item of capital equipment required
for Manufacturing the Product, the cost of acquiring such item of capital equipment itself, any engineering, installation, and/or validation costs relating to such capital equipment, and the costs of decommissioning or removing such capital
equipment, and (ii) with respect to Facility modifications, Biogen’s documented costs for making such modifications, and, as applicable, restoring the Facility to its prior state once such modifications are no longer needed, including
internal staff time, labor and materials costs and any testing, inspections and certifications required with respect to such modifications as set forth in Section 2.6.1. 

1.22 “[***]” has the meaning set forth in [***]. 

1.23 “Certificate of Analysis” means a document in Biogen’s standard format that sets forth the analytical test results for a specified
lot of Product or Batch to be released to Vir hereunder. 
 1.24 “Certificate of Conformance” means a document in Biogen’s standard
format that (i) is in conformance with Applicable Law and (ii) states whether such Product is manufactured in accordance with cGMPs and the defined Process; and (iii) confirms in writing that the applicable lot or Batch of Products
meets the applicable Specifications and acceptance criteria. 
 1.25 “cGMP” means current good manufacturing practices as set forth in the
regulations promulgated by the FDA under the U.S. Food, Drug and Cosmetic Act, 21 C.F.R. Part 210 et seq., as amended from time to time, applicable guidance documents issued by the FDA, EC Directive
2003/94/EC and EC Delegated Regulation 2017/1569 and European Medicines Agency guidance documents, and applicable documents developed by the International Conference on Harmonization (ICH), in each case to the extent that they are applicable to Drug
Substance or Drug Product and the Parties hereunder. 
 1.26 “Change Order” means an amendment to an SOW agreed to by the Parties in writing
in accordance with the terms set forth in Section 2.2. 
 1.27 “Commercial Supply Agreement” has the meaning set
forth in Section 2.1.3. 
 1.28 “Confidential Information” has the meaning set forth in
Section 6.1. 
 1.29 “Defective Product” has the meaning set forth in Section 4.3. 

1.30 “Deliverables” has the meaning set forth in Section 2.10.1. 

1.31 “Designated Drug Substance” has the meaning set forth in Section 2.10.2. 

1.32 “Development” or “Develop” means the activities to be performed hereunder by Biogen solely or in collaboration with Vir
directed towards creating or refining the Process for Manufacturing Drug Substance and Drug Product, as set forth in one or more SOWs. 
 1.33
“Deviation” means a departure from any of Biogen’s process, system, procedure, or other conformance standard. 
 1.34
“Discloser” has the meaning set forth in Section 6.1. 
 1.35 “Document Retention Period” has the
meaning set forth in Section 5.1. 
 1.36 “Drug Product” means drug product containing Drug Substance, as
identified in an SOW, and which is the subject of the Services to be provided pursuant to such SOW. 

  
 3 

 1.37 “Drug Substance” means a peptide, polypeptide or protein expressed by a cell line,
including any posttranslational modification thereof, as identified in the applicable SOW, and which is the subject of the Services to be provided pursuant to an SOW. For clarity, the SOWs under this Agreement shall be for antibodies directed to SARS-CoV-2. 
 1.38 “Effective Date” has the meaning set forth in
the introductory paragraph. 
 1.39 “Exception Notice” has the meaning set forth in Section 4.3. 

1.40 “Facility” means the Biogen facility located at [***], and/or the Biogen facility located at [***], and/or such other
facility(ies) as may be mutually agreed by the Parties and specified in an applicable SOW from time to time[***]. 
 1.41 “FDA” means
the U.S. Food and Drug Administration or any successor entity thereof having or performing substantially the same function. 
 1.42 “Fill
Finish” means the compounding, filling, producing and primary packaging of Drug Product in accordance with the applicable Specifications. 
 1.43
“[***]” means [***]. 
 1.44 “High-Value Materials” means all (i) bulk chromatography resins, (ii) Drug
Substance in API form when used in the Manufacturing of Drug Product, and (iii) other materials or components identified in an SOW as High-Value Materials, that in each case, are used in the Manufacture of Products and which are not Vir-supplied Materials. 
 1.45 “[***]” has the meaning set forth in [***]. 

1.46 “Improvements” means [***]. 
 1.47
“Inspection Period” has the meaning set forth in Section 4.3. 
 1.48 “Intellectual Property” has
the meaning set forth in Section 7.1. 
 1.49 “Invention” has the meaning set forth in
Section 7.1. 
 1.50 “JSC” has the meaning set forth in Section 2.12. 

1.51 “Latent Defect” has the meaning set forth in Section 4.4. 

1.52 “Letter of Intent” means the confidential letter of intent by and between Biogen and Vir dated March 3, 2020. 

1.53 “Losses” has the meaning set forth in Section 9.1. 

1.54 “Manufacturing” or “Manufacture” means the steps, processes and activities to produce cGMP Drug Substance or Drug
Product hereunder (as applicable), including, manufacturing, processing, packaging, labeling, testing, stability testing, process qualification, cell culture, purification, formulation and the release, shipping, storage or supply of Drug Substance
or Drug Product. 
 1.55 “Manufacturer” has the meaning set forth in Attachment C. 

  
 4 

 1.56 “Manufacturing Release” has the meaning set forth in
Section 2.9. 
 1.57 “Manufacturing Request” has the meaning set forth in Section 2.1.2.

 1.58 “Materials” means any antibody sequences, cDNA, mammalian cell line or other similar biologic material provided by or on behalf of
Vir to Biogen or by or on behalf of Biogen to Vir under this Agreement. 
 1.59 “non-cGMP” means,
with respect to any Product or Services, that such Product or Service is not intended to comply to cGMP, and, with respect to Products in particular, is not intended for use in humans. 

1.60 “OOS” has the meaning set forth in Section 3.1.6. 

1.61 “Party” means either Biogen or Vir, and “Parties” means both Biogen and Vir. 

1.62 “PPQ Batch(es)” means those process performance qualification Batches used to: (a) demonstrate and document the consistency and
reproducibility of a Manufacturing Process at a Facility; (b) establish the comparability of the applicable Product Manufactured at such Facility to Product manufactured by Biogen or another Third Party as required by the Regulatory
Authorities; and (c) support Regulatory Approval of both such Facility and such Manufacturing Process at such Facility. Each PPQ Batch is intended to produce Product that is or expected to be (following Regulatory Approval) commercially
saleable. 
 1.63 “Process” means the production process Developed hereunder and analytical methods for the Manufacture of the Drug
Substance or Drug Product, including any improvements or modifications thereto, comprising all technical information relating to the process of manufacture and testing reasonably required to produce such Drug Substance or Drug Product, including any
associated documentation, as set forth or referenced in the applicable Specification for such Product. 
 1.64 “Procured Equipment” has the
meaning set forth in Section 2.6.1. 
 1.65 “Product” means Drug Substance or Drug Product, as the context
requires. 
 1.66 “Project Documentation” means any interim or final analyses, written reports and records identified as deliverables in an
SOW. For the avoidance of doubt, documents that may be generated in the course of performing Services, but that are generally applicable to Biogen’s business, such as facility and equipment standard operating procedures (SOPs), will not
constitute Project Documentation. 
 1.67 “Project Manager” has the meaning set forth in Section 2.4. 

1.68 “Purchase Order” has the meaning set forth in Section 4.2. 

1.69 “QC Hold Waiver” has the meaning set forth in Section 5.6. 

1.70 “Quality Agreement” has the meaning set forth in Section 5.5. 

1.71 “Recipient” has the meaning set forth in Section 6.1. 

1.72 “Regulatory Approval” means, with respect to a country, all approvals, licenses, registrations or authorization by an applicable
Regulatory Authority, necessary to import Drug Substance or Drug Product, and to commercialize and market Drug Product. 

  
 5 

 1.73 “Regulatory Authority” means the international, federal, state or local governmental
or regulatory bodies, agencies, departments, bureaus, courts or other entities responsible for (i) the regulation (including pricing) of any aspect of pharmaceutical or medicinal products intended for human use or (ii) health, safety or
environmental matters generally. 
 1.74 “Representatives” of an entity means such entity’s duly-authorized officers, directors,
employees, agents, accountants, attorneys or other professional advisors. 
 1.75 “Services” means all work performed by Biogen for Vir
pursuant to an SOW. “Development Services” shall mean Services consisting of Development activities, “Technology Transfer Services” shall mean Services consisting of Technology Transfer activities,
“Manufacturing Services” shall mean Services consisting of pre-commercial/clinical Manufacturing activities as the context requires, and “Unplanned Services” shall have the
meaning as set forth in Section 3.1.6. 
 1.76 “SOW” means a separate statement of work agreed to and executed by
the Parties that defines the scope of work to be performed by Biogen and the responsibilities of the Parties with respect to such work, which statements of work shall be appended hereto at Attachment A as successive addenda upon execution
thereof by duly authorized representatives of each of the Parties. 
 1.77 “Specifications” means the written specifications for Drug
Substance or Drug Product, as applicable, agreed to by the Parties in an SOW, in each case as may be modified or amended by the mutual written agreement of the Parties from time to time. 

1.78 “Successful Batch(es)” has the meaning set forth in Section 1.8. 

1.79 “Technology Transfer” means the transfer, scale-up, testing, qualification, and licensure of a
Facility necessary to Manufacture a Product, including: (a) transfer of the Manufacturing Process to the Facility, including the Process description, technical information, Manufacturing documentation, analytical methods, reference standards,
materials, including, if stated in an applicable SOW, a portion of the master cell bank and/or working cell bank; (b) implementation of the Manufacturing Process at such Facility, including technical assistance and cooperation by appropriate
employees of Biogen [***]; (c) all Manufacturing Process fit activities to the extent mutually agreed in the applicable SOW, including required process development and validation work and process engineering required to modify/equip and
qualify such Facility for commercial Manufacturing; and (d) regulatory support for all required Regulatory Approvals of the Facility for commercial Manufacturing, each as relevant for the Facility in question and as further described in the
applicable SOW(s). 
 1.80 “Term” has the meaning set forth in Section 12.1. 

1.81 “Third Party” means any person, entity, or organization, including any government or sovereign, other than Biogen, Vir and their
respective Affiliates. 
 1.82 “Unplanned Services” has the meaning set forth in Section 3.1.6. 

1.83 “Vir” has the meaning set forth in the introductory paragraph, or any successor or permitted assign. 

1.84 “Vir Indemnitees” has the meaning set forth in Section 9.1. 

1.85 “Vir Invention” has the meaning set forth in Section 7.1. 

1.86 “Vir IP” has the meaning set forth in Section 7.1. 

  
 6 

 1.87 “Vir-Specific Items” has the meaning set forth
in Section 3.1.5. 
 1.88 “Vir-supplied Materials” means any Material
provided to Biogen for use in the Services by Vir, or by a Vir Affiliate or Third Party on behalf of Vir. 
 1.89 “[***]” means
[***]. 
 1.90 “[***]” means [***]. 

ARTICLE 2 
 SCOPE

 2.1 Services. This Agreement is intended to cover Development Services related to Drug Substance and Drug Product, and, pursuant to the terms
of this Section 2.1, Technology Transfer Services and Manufacturing Services for the pre-commercial/clinical supply of Product. The JSC shall discuss any potential Manufacturing needs
of Vir related to Product as applicable. The Parties acknowledge and agree that (a) prior to the Effective Date, certain activities have been conducted under the Letter of Intent, including with respect to cell line development (the
“Prior Development Activities”), which are applicable to the Services to be conducted hereunder, and (b) the Prior Development Activities shall be deemed to be Services conducted under this Agreement, and subject to the terms
set forth herein, and (c) this Agreement shall be retroactively effective with respect to all Prior Development Activities and all Confidential Information disclosed by either Party in connection with such Prior Development Activities, from and
after March 3, 2020. 
 2.1.1 Statements of Work; Conflict. Biogen shall use commercially reasonable efforts to perform the
Services in accordance with the specific terms set forth in each SOW, provided that Biogen shall use commercially reasonable efforts to perform any activities related to Technology Transfer pursuant to this Section 2.1
and/or Section 2.5, in each case that are allocated to Biogen under an applicable SOW, in each case in accordance with the timelines set forth therein. Each SOW shall clearly define (as applicable) the Services, Vir-supplied Materials, other Materials, Drug Substance and/or Drug Product to be manufactured thereunder, Specifications, and the responsibilities of the Parties with respect to the SOW. No single SOW shall require
more than [***]. Each SOW will include, as appropriate, the scope of work, pricing and payment schedule. Each SOW shall be subject to, and shall incorporate by reference, all of the terms and conditions of this Agreement. To the extent any
terms or conditions of an SOW conflict with the terms and conditions of this Agreement, the terms and conditions of this Agreement shall control, except to the extent that the applicable SOW expressly and specifically states that it supersedes this
Agreement on a specific matter. This Agreement shall supersede the terms of any purchase order, acknowledgement or delivery document. This Agreement shall not modify in any way the terms of any other development, license, manufacturing, packaging or
other agreement between Vir and Biogen or their respective Affiliates. Vir agrees that [***], and any termination of such SOW by Vir shall be subject to Section 12.4. 

2.1.2 Pre-Commercial/Clinical Manufacturing and Supply. As soon as reasonably practicable
following the Effective Date, the Parties will discuss and agree upon the pre-commercial/clinical Manufacturing capacity for pre-commercial/clinical Manufacturing of
Product at Biogen’s Facilities subject to this Section 2.1.2 and [***], in order to guide Vir’s forecasting for Product pursuant to Section 4.1. If Biogen, [***], is able to
commit to providing sufficient Manufacturing capacity to Vir for pre-commercial/clinical supply of Product during the Term, and, if Vir wishes Biogen to perform Manufacturing Services under this Agreement, Vir
shall submit such request for Manufacturing Services formally to Biogen in accordance with the notice procedures set forth in Article 13 (a “Manufacturing Request”). Promptly following Biogen’s receipt of a Manufacturing
Request, the JSC shall discuss such Manufacturing Request, provided that Biogen may, in its sole and absolute discretion, for any or no reason 

  
 7 

 
whatsoever, accept or reject such Manufacturing Request within [***]. If Biogen does not affirmatively accept such Manufacturing Request within [***] Biogen will be deemed to have rejected such
Manufacturing Request. Biogen’s obligation to perform Manufacturing Services shall be further subject to the execution by the Parties of mutually agreeable SOWs for Manufacturing Services, as further set forth in
Section 2.2. Without limiting the foregoing, the Parties agree that as of the Effective Date, (a) Vir has submitted, and Biogen has accepted, a Manufacturing Request for the Manufacture of certain Batches of Drug
Substance and a to-be-agreed-upon amount of Drug Product, which Manufacturing Request is attached to this Agreement as Attachment D, (b) the Parties have
agreed upon the terms of SOW A-1 governing the process development of Drug Substance specified in such Manufacturing Request (the “Process Development SOW”), (c) the Parties have agreed upon
the terms of SOW A-2 governing the Manufacture of the Drug Substance specified in such Manufacturing Request (the “Initial DS SOW”) and (d) the Parties have agreed upon the terms of SOW A-3 governing Manufacture of the Drug Product specified in such Manufacturing Request (the “Initial DP SOW”). The Process Development SOW, Initial DS SOW and Initial DP SOW are attached to this
Agreement as Attachment A-1, Attachment A-2 and Attachment A-3 respectively. The quantities, dosages and
timing of Drug Product Manufacturing Services will be as defined in a mutually agreeable SOW(s). 
 2.1.3 Commercial Manufacturing and
Supply. As of the Effective Date, the Parties do not intend that commercial-scale Manufacturing be conducted under this Agreement. Notwithstanding the foregoing, in anticipation of the potential negotiation of a commercial-scale manufacturing
agreement (a “Commercial Supply Agreement”), the Parties may discuss the possibility of [***] including the possibility of Biogen (i) [***], (ii) [***] and (iii) [***]. Further, neither Party is obliged to
negotiate or enter into a Commercial Supply Agreement [***]. 
 2.2 Amendments to Scope/Change Orders. Any material change in the details of an
SOW or the assumptions upon which the SOW is based, including, but not limited to (i) [***], (ii) [***], or (iii) [***], may require changes in the pricing and time lines, [***], and in all events shall require a written amendment to the SOW
(a “Change Order”). Each Change Order shall detail the requested changes to the applicable task, responsibility, duty, pricing, timeline or other matter. The Change Order will become effective upon the execution of the Change Order
by both Parties, and Biogen will be given a reasonable period of time within which to implement the changes. Both Parties shall act in good faith and promptly when considering a Change Order requested by the other Party. Without limiting the
foregoing, Vir shall not [***]. Biogen shall not be obligated to perform any modified or additional Services until a Change Order has been executed by the Parties with respect to such Services. 

2.3 Vir Responsibilities. Unless otherwise agreed by the Parties in writing or in the SOW, Vir agrees that it shall (i) provide current and
accurate scientific data in Vir’s possession and control regarding each project described in an SOW and its requirements for such project, including test methods and data and methods concerning Development, formulation, fill and finish of the
Product if applicable, in each case to the extent necessary for Biogen to perform its responsibilities under a SOW (ii) provide Biogen with information necessary to develop each SOW, including information reasonably required to prepare the
scope of work and provide estimated or fixed costs, (iii) use commercially reasonable efforts to perform the activities identified as its responsibility in each SOW in accordance with the timelines set forth therein; (iv) review and
approve all Specifications for work or Product, (v) if applicable, review and approve all in-process and finished Product test results to ensure conformity of such results with the agreed Product
Specifications, regardless of which Party is responsible for finished Product release, and (vi) if applicable, prepare all submissions to Regulatory Authorities in connection with the Product. 

2.4 Project Managers. Each Party shall designate one project manager for each SOW (each a “Project Manager”), who shall be responsible
for making technical and operational decisions relating to such SOW, as well as communicating to each other technical and operational issues regarding the Services. 

  
 8 

 2.5 Technology Transfer. The Parties intend that all Manufacturing Processes Developed by Biogen
under any applicable Development SOW(s) shall be portable by Vir from one Facility to another Facility, or to a facility of any Third Party that Vir designates in writing to Biogen from time to time for the conduct of
pre-commercial/clinical and commercial Manufacturing, provided, however, Biogen does not guarantee the successful implementation of any Manufacturing Processes at Third Party facilities. Upon the expiration of
this Agreement or its termination by Vir pursuant to Sections 12.2 or 12.3, or at Vir’s written request at any other time during the Term, Biogen shall use commercially reasonable efforts to perform a Technology Transfer of the
Manufacturing Process to a Biogen Facility, to Vir or its Affiliates, or to a Third Party contractor designated by Vir. Vir acknowledges that such documentation and materials will [***]. Certain [***] required to Manufacture the
Process will be made available to Vir through arrangements with Biogen’s suppliers pursuant to Section 7.5.4. Subject to Section 3.1.2, Vir shall reimburse Biogen on a reasonable hourly-rate
basis for such technical assistance as further defined in the applicable SOW(s) governing Technology Transfer activities. In no event shall Biogen be obliged to perform any activities under this Section 2.5 after
[***] of the date of expiration or termination of this Agreement. 
 2.6 Capital Modifications, Expenditures and Maintenance. 

2.6.1 Equipment and Capital Costs. Biogen will provide to Vir for review and prior written approval a budget of the Capital Costs to be
incurred by Biogen for any capital equipment or Facility modifications required to Manufacture the Product in a Facility. [***]. Unless the Parties agree to a different reimbursement arrangement within an applicable SOW, Vir shall reimburse
Biogen for the Capital Costs for the capital equipment or the making of Facility modifications in each case [***] (all of the foregoing, the “Procured Equipment”). Ownership of the Procured Equipment shall vest in Biogen and,
unless otherwise mutually agreed in writing by the Parties, shall (a) be marked “Vir Use Only”, and (b) be used solely by Biogen for Manufacture of the Product under the applicable SOW(s). 

2.6.2 Maintenance. Biogen shall be responsible for routine maintenance of Procured Equipment. Vir shall be responsible for the cost of
any non-routine repair or replacement, of Procured Equipment used in the Process which is required during the Term (other than in connection with any damage or destruction to the extent resulting from the
negligence or willful misconduct of Biogen). Upon Vir’s prior written consent, Biogen shall repair or replace such equipment and Biogen shall invoice Vir for such for repair expenses or capital for the replacement on the basis of the relevant
cost therefor, and Vir shall pay all such invoices in accordance with Article 3. 
 2.6.3 Facilities. Biogen shall not be
required to make a modification to a Facility, or to implement a Process, that is not fundamentally compatible with the Facility, including equipment used in and Manufacturing processes performed in such Facility, as established by Biogen.
[***]. 
 2.7 Vir-supplied Material; High-Value Materials. 

2.7.1 Provision. Except as expressly set forth in an SOW, Vir will provide all samples, reference materials, and other Materials, as
applicable, required for each SOW. [***] and Vir shall be responsible for forecasting and ordering from Biogen, in accordance with this Agreement, sufficient quantities of Drug Substance, including a mutually agreed allowance for loss, to
enable Biogen to Manufacture Drug Product in accordance with the applicable forecasts, SOW(s) and Purchase Orders. Vir shall be responsible at its expense for securing any necessary export or import, or similar clearances, permits or certifications,
including U.S. Drug Enforcement Administration (DEA) licenses, required in respect of such supply. Biogen shall use such items solely for use in the Services. Prior to delivery of any such items, Vir shall provide to Biogen a copy of all associated
material safety data sheets, safe handling instructions and health and environmental information, and any regulatory certifications or authorizations that may be required under Applicable Laws relating to
Vir-supplied Materials, and shall promptly provide any updates thereto. 

  
 9 

 2.7.2 Responsibilities for Vir-supplied
Materials. Following receipt of Vir-supplied Materials, Biogen shall visually check such items to verify their identity and assess for any visible non-conformance
with the specifications relating thereto. Unless otherwise expressly required by the Specifications, or the applicable SOW, Biogen shall have no obligation to test such items to confirm that they meet the associated specifications or certificate of
analysis or otherwise; but if Biogen detects a nonconformity with applicable specifications, Biogen shall give Vir prompt written notice of such nonconformity. Biogen shall not be liable for any defects in
Vir-supplied Materials, or in Services, Drug Product as a result of defective Vir-supplied Materials, unless Biogen failed to properly perform the foregoing obligations.
Biogen shall follow Vir’s reasonable written instructions in respect of return or disposal of defective Vir-supplied Materials, at Vir’s cost. Vir shall retain title to
Vir-supplied Materials at all times and shall bear the risk of loss thereof, except for any loss resulting from Biogen’s gross negligence or willful misconduct. 

2.7.3 Delays. Biogen reserves the right to cancel or postpone, [***], all or any part of an SOW upon written notice to Vir if Vir
fails to timely supply conforming Vir-supplied Materials. In the event of such cancellation, Biogen shall comply with Article 12, and except as set forth therein, shall have no further obligations or
liability with respect to the affected SOW. In the event of such postponement, Biogen shall reschedule the work at the next available slot following receipt of conforming Vir-supplied Materials. [***].

 2.7.4 High-Value Materials. Notwithstanding any provision herein to the contrary, except as otherwise set forth in an SOW,
[***]. For clarity, in the case of Manufacturing by a Biogen subcontractor at a Third Party Facility, Vir’s obligation to pay replacement costs under this Section 2.7.4 shall not apply to the extent Biogen is
not obligated to pay equivalent replacement costs for loss of High-Value Materials at a Third Party Facility under the terms of Biogen’s agreement with such Third Party 

2.8 Error. Except with respect to pre-commercial/clinical Manufacturing Services (which, for clarity, are
subject to Section 4.3), in the event of a material error by Biogen (including as a result of gross negligence) in performing any Services which renders the results unacceptable to a regulatory agency or Regulatory
Authority to which Vir intends to submit such results, Biogen’s sole obligation to Vir shall be for Biogen to repeat the relevant Services at Biogen’s own cost. In such event, Vir shall supply, at its cost, Biogen with sufficient
quantities of Vir-supplied Materials in order for Biogen to complete such re-performance and Biogen shall schedule and complete such
re-performance at the earliest possible date. 
 2.9 Release. This Section 2.9
applies solely to Manufacturing Services and does not apply to Development Services. Drug Substance and Drug Product shall be released by Biogen only when [***] (collectively, “Manufacturing Release”). Biogen shall
keep Vir reasonably updated as to the proposed schedule and time for Manufacturing Release of each Batch of Drug Substance and Drug Product. Biogen shall notify Vir without undue delay if Biogen becomes aware that it will or has reason to believe
that it may be unable to meet the previously estimated date for Manufacturing Release of the applicable Drug Substance or Drug Product. In the event of such a delay for a particular Batch, Biogen shall notify Vir of the reason for the delay. For
clarity, unless otherwise set forth in an SOW, Vir shall be responsible for the final release of Drug Product. 
 2.10 Delivery; Title and Risk of
Loss. 
 2.10.1 Delivery Terms. Biogen shall deliver all master cell banks and working cell banks, Drug Substance, Drug Product,
samples, and other tangible items specified as deliverables in an SOW or this Agreement (collectively, the “Deliverables”) [***]. 

  
 10 

 2.10.2 Drug Substance and Drug Product. Biogen shall retain title to and risk in Drug
Substance that is designated for conversion to Drug Product by Biogen (“Designated Drug Substance”) for a period of [***]. To the extent not already held by Vir, and except for Designated Drug Substance held by Biogen, title
to the Deliverables shall transfer to Vir upon [***]; provided, however, that Biogen shall [***]. Except for Designated Drug Substance, risk of loss in the Deliverables shall transfer to Vir upon [***]. Vir shall arrange for
collection of Drug Substance and Drug Product within [***], except for Designated Drug Substance. Designated Drug Substance will become part of Biogen’s
work-in-process at the time when it is first used in the Process for Drug Product. Notwithstanding anything herein, if Vir’s Purchase Orders for Drug Product are
for quantities of Drug Product that are insufficient to absorb all of the Designated Drug Substance (on a first-released, first-used basis) within [***] of the Designated Drug Substance, risk in and title to the excess Designated Drug
Substance shall be deemed to transfer to Vir upon [***]. For clarity, this Section 2.10.2 only applies to the extent Biogen has accepted a Manufacturing Request in accordance with
Section 2.1.2. 
 2.10.3 Storage of Cell Banks. Biogen will store all master cell bank(s)and/or working cell
bank(s) developed by Biogen or received by Biogen as Vir-supplied Material (including [***]) in accordance with the applicable SOW(s) for Services and the Specification. Biogen shall not permit the
transfer of the master cell bank(s)and/or working cell bank(s) to any facility that is not specifically authorized in advance and in writing by Vir. Vir will only send Biogen the quantity of [***] requested by Biogen under the terms of the
applicable SOW. For clarity, Section 6.7 shall apply to [***]. 
 2.10.4 Project Documentation.
Biogen shall deliver Project Documentation in accordance with any documentation delivery dates set forth in an SOW, subject to reasonable extensions of time for any Project Documentation that is affected by any Change Order or delay as set forth
elsewhere herein. Biogen may deliver Project Documentation in a customary and mutually acceptable electronic format as further described in an SOW. Biogen shall have the right to (i) retain copies of any Project Documentation that it is
required to retain by Applicable Laws, including retaining original records if so required by Applicable Laws, and (ii) use such Project Documentation solely for purposes of compliance with cGMP requirements or Applicable Laws, or for any other
use expressly stated in an SOW. Furthermore, [***]. For clarity, this Section 2.10.4 only applies to the extent Biogen has accepted a Manufacturing Request in accordance with Section 2.1.2.

 2.10.5 Samples and Excess Materials. Following completion of each relevant phase of an SOW, samples will be stored in quarantine at
the Facility in accordance with Applicable Laws. After [***], Biogen will dispose of samples, at Vir’s cost, unless prior written instructions have been provided by Vir for returning samples to Vir at Vir’s cost. Biogen will also
dispose of unused Vir-supplied Materials within [***] of the termination of the relevant SOW, at Vir’s cost, unless prior written instructions have been provided by Vir for returning such materials
to Vir at Vir’s cost. 
 2.11 Subcontractors. Subject to the other terms and conditions of this Agreement, Biogen reserves the right to employ
subcontractors to undertake certain Services upon prior written notice to Vir, which notice shall identify the subcontractor and describe the activities to be performed by such subcontractor. [***]. Any subcontractors engaged by Biogen to
provide any part of the Services will be subject to written obligations consistent with those applicable to Biogen under this Agreement, including with respect to any confidentiality obligations and ownership of the Deliverables and Inventions. 

2.12 Joint Steering Committee. Promptly following the Effective Date, the Parties shall establish a joint steering committee (the
“JSC”). The JSC shall oversee and review Development, Technology Transfer, and Manufacturing activities for clinical supply in connection with Drug Product and Drug Substance, [***]. The JSC shall be responsible for
monitoring the need for Drug Substance and Drug Product in the context of the global incidence and prevalence of
SARS-CoV-2/COVID-19. To that end, Vir shall share with the JSC periodic non-binding
forecasts for its clinical and commercial requirements for Drug Substance and Drug Product to facilitate planning and the discussion of potential Manufacturing Requests 

  
 11 

 pursuant to Section 2.1.2 as well as the potential negotiation of a Commercial
Supply Agreement pursuant to Section 2.1.3. Any forecasts provided under Section 4.1 shall supersede any informational forecasts provided under this Section 2.12.
The JSC shall be comprised of at least one (1) representative (or such other number of representatives as the Parties may mutually agree) from each of Biogen and Vir. Each Party’s Project Manager shall be a non-voting member of the JSC. Upon its formation, the JSC shall meet in person or by teleconference at least [***] following the Effective Date, and thereafter at least [***], or more or less
frequently as the Parties mutually deem appropriate, provided that the JSC shall meet at least [***]. All decisions of the JSC shall be made by consensus, with each Party having one (1) vote; provided that Biogen shall have final
decision-making authority with regard to Biogen’s capacity to Manufacture Drug Substance and/or Drug Product. If the JSC cannot agree on a matter within [***] after it has attempted to reach such decision in good faith, then, with the
exception of capacity questions, which shall be decided solely by Biogen, the matter shall be escalated for resolution to a senior executive nominated by each Party. If such senior executives cannot resolve the matter within [***] following
referral, the status quo shall prevail with respect to such matter. 
 ARTICLE 3 

PAYMENTS 
 3.1 Fees. 

3.1.1 Fees—Development Services. Vir shall pay for the Development Services as provided in this Agreement and each applicable SOW
for Development Services. 
 3.1.2 Fees – Technology Transfer Services. Vir shall pay for any services relating to Biogen’s
performance of Technology Transfer services as provided in this Agreement and each applicable SOW for such Technology Transfer services, including any Third Party testing services that may be requested by Vir (or recommended by Biogen and accepted
by Vir) as part of the Technology Transfer services. Such Third Party testing services shall be paid by Vir on a pass-through basis. 
 3.1.3
Fees – Manufacturing Services. Vir shall pay for the Manufacturing Services as provided in this Agreement and each applicable SOW for Manufacturing Services. For avoidance of doubt, Vir shall be responsible for all costs payable
to Third Parties for Manufacturing at the Third Party’s Facility, including any Third Party testing services that may be required as part of such Manufacturing Services, unless otherwise agreed with Biogen pursuant to
Section 2.1. Any Third Party testing services that may be required as part of the Manufacturing Services shall be specified in SOPs developed for the Process and shall be paid by Vir on a pass-through basis. In addition to
the fees for the performance of the Manufacturing Services set forth in this Agreement and each SOW for Manufacturing Services, Vir agrees to pay the access fees specified in the Attachment C (“Access Fees”) for all
Manufacturing of Products using any Improvements whether such Manufacturing is performed directly by Vir, its Affiliates or its or their licensees or collaborators or by Third Parties contracted by any of the foregoing. 

3.1.4 Price Changes. With the exception of [***], Biogen may reasonably revise the fees provided in an SOW if (i) any
information relating to an SOW which is provided by Vir is materially inaccurate or incomplete, and such inaccurate or incomplete information directly and adversely impacts the costs of Biogen providing the Services, or (ii) pursuant to a
Change Order, there is a material revision to the scope of Services under the applicable SOW or Biogen’s responsibilities thereunder. In addition, the fees provided in an SOW [***] shall be subject to annual review by the Parties to
address changes in inflation, increased overhead charges, and other commercially reasonable factors. 

  
 12 

 3.1.5 Vir-Specific Purchases. Vir shall be
responsible for the costs of all Materials, reference standards, specialty chemicals, and other Vir-specific purchases required to perform the Services, including any High-Value Materials not supplied by Vir
(collectively, “Vir-Specific Items”), [***] unless provided by Vir to Biogen at no cost as Vir-supplied Materials pursuant to
Section 2.7. Vir shall be responsible for the costs of replacing any Vir-Specific Items that become obsolete prior to their scheduled use in Manufacturing Drug Substance or Drug
Product, provided that Biogen shall manage inventory of Vir-Specific Items in order to minimize the chances of obsolescence. 

3.1.6 Unplanned Services. Biogen will notify Vir of the cost of performing any unplanned investigational studies, out of specification
(“OOS”) investigations or additional Vir-requested retesting Services not otherwise specified in an SOW (collectively, “Unplanned Services”), and subject to Vir’s
approval, not to be unreasonably withheld, of the applicable Change Order for said Unplanned Services in accordance with Section 2.2, Biogen will invoice Vir for the cost of performing these Unplanned Services provided that
any Unplanned Services directly due to a Biogen error will be subject to Section 2.8. 
 3.1.7 Cancellations and
Postponements. 
 (a) SOWs for Batch Manufacture or Fill Finish pursuant to Section 2.1 shall be non-cancellable with respect to any part within the Binding Forecast. 
 (b) With respect to Services other
than Batch Manufacture or Fill Finish (which, for clarity, are subject to Section 3.1.7(a)), if Vir [***], then Vir shall pay Biogen any applicable cancellation fees set forth in the applicable SOW. 

(c) Notwithstanding Sections 3.1.7(a) and 3.1.7(b), Biogen shall [***] to reallocate any Service resources and materials
or manufacturing slots vacated by any such cancellation or postponement to Biogen, other customers of Biogen, or, if agreed by Vir, other Vir projects conducted by Biogen under separate a separate SOW in order to mitigate any losses arising from
such postponement or cancellation, and Vir shall only be liable for the remainder of any Binding Forecast or for cancellation fees, as applicable, in connection with Service resources and materials or manufacturing slots left vacant and unable to be
filled by Biogen, other customers of Biogen, or other Vir projects. 
 3.2 Invoicing. Unless otherwise provided in the applicable SOW, Biogen shall
invoice Vir as follows: 
 3.2.1 for Batch Manufacture and/or Fill Finish pursuant to Biogen’s acceptance of a Manufacturing Request
pursuant to Section 2.1.2 upon the earliest to occur of the following: (i) [***]; (ii) [***]; or (iii) if a Third Party is to perform finished product testing, then [***] following shipment of Drug
Substance or Drug Product samples to a Third Party testing agency, but only if such testing agency has not yet delivered its test results for such Drug Substance or Drug Product and Biogen has performed all of its responsibilities except for those
responsibilities which incorporate test results from the Third Party testing agency; 
 3.2.2 for any SOW that can be completed within
[***] (other than Batch Manufacture and/or Fill Finish), Biogen shall invoice Vir upon [***]; 
 3.2.3 for any SOW that cannot
be completed within [***] (other than Batch Manufacture and/or Fill Finish), Biogen shall invoice Vir [***], or as set forth on the applicable SOW; 

3.2.4 for any Vir-Specific Items other than High-Value Materials, Biogen shall invoice Vir for such Vir-Specific Items with the invoice for the Batch for which such Vir-Specific Items were ordered. The costs of High-Value Materials, shall be invoiced when purchased by
Biogen, provided that the [***] fee set forth in Section 3.1.5 shall be pro-rated across the Batches for which such High-Value Materials are used, with the balance (if any) of
such fee to be invoiced if and when such High-Value Materials become obsolete or if the applicable SOW or this Agreement is terminated; or 

  
 13 

 3.2.5 for any milestone payment, Biogen shall invoice Vir when the milestone trigger event
occurs. 
 3.3 Payment Terms. Payment of all Biogen invoices shall be due [***] after the date of receipt of invoice, subject to
Section 3.4 with respect to any disputed amounts. Vir shall make payment in U.S. dollars, and otherwise as directed in the applicable invoice. If any payment is not received by Biogen by its due date, then [***].

 3.4 Method of Payment. Unless otherwise specified in an SOW, all undisputed amounts payable to Biogen under this Agreement will be paid in U.S.
Dollars, without deduction, and by authenticated and value dated Swift telegraphic transfer for any such payments made from outside the U.S., quoting invoice numbers of payment to the bank account identified in the applicable invoice or by such
other means as Biogen will notify Vir in writing from time to time. If Vir disputes the amount of any invoice, it shall notify Biogen within [***] following receipt of the invoice, and the Parties shall meet within [***] following such
notice to seek to resolve such dispute. 
 3.5 Taxes. All taxes, duties and other amounts assessed (excluding tax based on net income and franchise
taxes) on Services, Procured Equipment, components, Drug Substance or Drug Product prior to or upon provision or sale to Biogen or Vir, as the case may be, and on any other Vir-supplied Materials, are the
responsibility of Vir, and Vir shall reimburse Biogen for all such taxes, duties or other expenses paid by Biogen or such sums will be added to invoices directed to Vir, where applicable. If any deduction or withholding in respect of tax or
otherwise is required by law to be made from any of the sums payable hereunder, Vir shall be obliged to pay to Biogen such greater sum as will leave Biogen, after deduction or withholding as is required to be made, with the same amount as it would
have been entitled to receive in the absence of any such requirement to make a deduction or withholding. For clarity, all prices and amounts due set forth herein are stated exclusive of any value added tax, goods and services tax or other forms of
sales tax. 
 ARTICLE 4 

MANUFACTURING AND FILL FINISH 
 To the
extent Biogen has accepted a Manufacturing Request in accordance with Section 2.1.2, subsequent to which the Services include pre-commercial/clinical Manufacturing and/or Fill Finish,
the following shall apply except to the extent that the Parties otherwise agree in writing. The Parties acknowledge that [***]. 
 4.1
Forecasts. 
 4.1.1 Initial Forecast. At the first meeting of the JSC following the acceptance of a Manufacturing Request by
Biogen, or at such other time as may be agreed in writing by the Parties, Vir shall provide Biogen with an initial forecast consistent with the provisions of this Agreement and Biogen agrees to confirm, reject or otherwise respond to Vir within
[***] thereafter to such initial forecast. 
 4.1.2 Forecast Length. The initial forecast shall cover the next [***]
(or the period covered by the Parties’ [***]), setting forth the timing and number of Campaigns to be conducted and Batches of Drug Substance and Drug Product (as applicable) that Vir expects to order from Biogen during this period and
which is consistent with the Manufacturing capacity agreed by Biogen pursuant to Section 2.1.2. Within [***] prior to the beginning of each calendar quarter, Vir shall submit to Biogen a rolling written forecast of
its requirements of pre-commercial/clinical Product to be supplied by Biogen during the remainder of the agreed forecast period. 

  
 15 

 4.1.3 Binding and Non-binding
Portions. [***]. Each forecast made under Section 4.1 shall include a forecast of the total quantity of each Product (in Batches, kilograms or other relevant unit) that will be required for the [***]
(each, a “Binding Forecast”). The forecast for the subsequent [***] (the “Advisory Forecast”) shall include the total quantity of each Product reasonably anticipated to be made during such [***]. The
Parties acknowledge that each Binding Forecast shall be binding as set forth above in [***], and will represent a binding commitment for Vir or its Affiliate(s) to pay for the number of Batches needed to produce such forecasted Product in
such [***]. The Project Managers shall be responsible for scheduling the Manufacturing to meet Vir’s Binding Forecast, subject to the terms of this Section 4.1.3. [***]. 

4.1.4 [***]. 
 4.2 Orders. Vir shall
deliver to Biogen, together with each Binding Forecast, a written binding purchase order (each, a “Purchase Order”) for the amount of Product that Vir wishes to order during the first calendar quarter covered by such Binding
Forecast. For further clarity, the Parties acknowledge and agree that Batches must be forecasted and ordered in full Batch increments; forecasts and orders for partial Batches will not be accepted unless otherwise set forth in a SOW. Biogen shall
provide Vir with written notice (but in any event within [***]) of its acceptance of each such Purchase Order. If Biogen fails to provide notice to Vir of acceptance within such [***] period, such Purchase Order shall be deemed
accepted. Biogen shall [***] provide Vir with Product in quantities sufficient to fulfill Vir’s Purchase Order, in accordance with the delivery dates set forth in the applicable Purchase Order. [***]. Notwithstanding the
foregoing, Biogen shall have the right to reject any quantities of Product within any Purchase Order that exceed [***] of the quantity of the applicable Product forecasted by Vir for the relevant period in the most recent Binding Forecast,
provided that Biogen shall [***] any, Purchase Order for quantities up to [***] of the most recent Binding Forecast. If Biogen in its discretion determines to accept any Purchase Order greater than [***] of the most recent
Binding Forecast, Biogen shall [***] to supply Vir with such excess Manufacturing capacity and/or quantities, as applicable. Each Purchase Order shall specify: (i) the quantity of Product to be made under each Campaign, (ii) the
requested location for delivery of each Successful Batch; (iii) the requested time of delivery of each Successful Batch; (iv) the carrier and/or manner of shipment that Biogen should use in delivering each Successful Batch; and
(v) the Materials to be ordered by Biogen for supply of Product to Vir or Vir-supplied Materials to be provided directly by Vir to Biogen for use in the Manufacture of Product. [***]. 

4.3 Nonconforming Drug Substance or Drug Product. Subject to Sections 4.4 and 4.5, unless within [***] after tender of delivery of
Drug Substance or Drug Product, as applicable (the “Inspection Period”), Vir or its designee notifies Biogen in writing (an “Exception Notice”) that such Drug Substance or Drug Product does not meet the warranty set
forth in Section 8.1.4 (“Defective Product”), and provides a sample of the alleged Defective Product, the Drug Substance or Drug Product shall be deemed accepted by Vir, and Vir shall have no right to
reject such Drug Substance or Drug Product. Upon timely receipt of an Exception Notice from Vir, Biogen shall conduct an appropriate investigation to determine whether or not it agrees with Vir that Drug Substance or Drug Product is Defective
Product and to determine the cause of any nonconformity. If Biogen agrees that Drug Substance or Drug Product is Defective Product and determines that the cause of the nonconformity is attributable to [***], then Vir shall not be responsible
to pay for such Defective Product, and Biogen shall, [***]. 

  
 15 

 4.4 Latent Defects. For the purposes of this Agreement, a “Latent Defect” means a
defect or other condition that causes Drug Substance or Drug Product to be Defective Product that [***]. In the case of discovery of any Latent Defect, Vir will have [***] after discovery of such Latent Defect to notify Biogen of such
Latent Defect. Where Vir provides Biogen with an Exception Notice in connection with the existence of a Latent Defect, the Parties shall [***], and if Biogen agrees that Drug Substance or Drug Product is Defective Product as a result of
Biogen Defective Processing, then Biogen shall, [***]. 
 4.5 Discrepant Results. If the Parties disagree as to whether Drug Substance or Drug
Product is Defective Product (whether under Section 4.3 or Section 4.4) and/or whether the cause of the nonconformity is Biogen Defective Processing, and the disagreement is not resolved within
[***] (or such other period as may be agreed in writing by the Parties) of the Exception Notice date, the Parties shall cause a mutually acceptable independent Third Party to review records, test data and to perform comparative tests and/or
analyses on samples of the alleged Defective Product and its components, including Vir-supplied Materials. [***]. Unless otherwise agreed to by the Parties in writing, the costs associated with such
testing and review shall [***]. 
 4.6 [***]. Subject to the provisions of this Section 4.6, and to
[***], Vir agrees that [***]. 
 ARTICLE 5 

REGULATORY 
 The requirements set forth in
this Article 5 shall apply to the Services to the extent required by Applicable Laws. Vir acknowledges and agrees that the Development Services shall be performed on a non-cGMP basis and that the laws,
regulations and guidelines governing cGMP Manufacturing shall not be deemed to apply to the Development Services unless otherwise requested by Vir and specified in the applicable SOW. For clarity, this Article 5 applies to Technology Transfer
services agreed by the Parties but only applies to Manufacturing Services to the extent Biogen has accepted a Manufacturing Request in accordance with Section 2.1.2. 

5.1 Recordkeeping. Unless the Parties otherwise agree in writing, Biogen shall maintain [***] complete and accurate Batch Records, laboratory
data, reports and other technical records relating to Drug Substance or Drug Product in accordance with Biogen standard operating procedures and Applicable Laws. Such records shall be maintained for [***] (the “Document Retention
Period”). Following the expiry of the Document Retention Period, and prior to disposing of or destroying such documentation, Biogen shall first offer to deliver such documentation to Vir. If Vir refuses in writing the delivery of such
documentation or fails to respond to such offer within [***], Biogen may destroy such documentation. 
 5.2 Regulatory Compliance. Biogen shall
obtain and maintain all permits and licenses with respect to general Facility operations required by any Regulatory Authority in the jurisdiction in which Biogen performs Services. Vir shall obtain and maintain all other Regulatory Approvals,
authorizations and certificates, including those with respect to Drug Substance or Drug Product. Vir shall [***]. Vir shall not identify Biogen in any regulatory filing or submission without Biogen’s prior written consent. Such consent
shall not be unreasonably withheld or delayed and shall be memorialized in a writing signed by authorized representatives of both Parties. Upon written request, Vir shall [***]. During the Term, Biogen will provide information to Vir as
reasonably needed for regulatory filings and inquiries by Regulatory Authorities relating to Drug Substance or Drug Product, at Vir’s request and expense; provided, however, that Biogen may [***]. Vir shall provide to Biogen all
information concerning Drug Substance and Drug Product and related Regulatory Approvals, authorizations and certificates in Vir’s possession as reasonably required to allow Biogen to satisfy its obligations under Applicable Laws relating to
performance of this Agreement. 

  
 16 

 5.3 Governmental Inspections and Requests. Each Party shall promptly advise the other Party of any
inspection or inquiry by any Regulatory Authority concerning any SOW, Drug Substance or Drug Product. Biogen shall, subject to any Third Party facility or subcontractor restrictions if applicable, permit up to [***] of Vir to be present at
any inspection relating specifically to Services under this Agreement, provided that Vir may be excluded from any part of the Facility or inspection that does not [***] to the Services or Product, and Vir shall not have the right to direct
Biogen’s conduct of any such inspection. Upon request, Biogen shall, subject to any Third Party facility or subcontractor restrictions if applicable, provide Vir with a copy of any report issued by such Regulatory Authority received by Biogen
following a visit to the Facility concerning the Drug Substance or Drug Product, redacted as appropriate to protect any confidential information of Biogen and Biogen’s other customers; and Vir shall provide Biogen with any [***]
correspondence with such Regulatory Authority, including FDA refusal to file, rejection or warning letters. Vir acknowledges that it may not direct the manner in which Biogen fulfills its obligations to permit inspection by and to communicate with
Regulatory Authorities. Vir shall [***]. 
 5.4 Facility Audits and Observation. This Section 5.4 only applies to
Technology Transfer Services and Manufacturing Services and does not apply to Development Services. 
 5.4.1 Quality
Audits. During the Term, Vir’s Representatives shall be granted access upon at least [***] prior notice, at reasonable times during regular business hours, and subject to any Third Party facility or subcontractor
restrictions if applicable, to (i) the portion of the Facility where Biogen performs Services, (ii) relevant personnel involved in Services and (iii) Services records described in Section 5.1, in each case
[***] for the purpose of verifying that Biogen is performing Services in accordance with cGMPs, Applicable Laws, the Specifications and the master Batch records, as applicable. Vir may not conduct an audit under this
Section 5.4.1 more than [***] during any [***] period; provided that additional inspections may be conducted in the event there is a [***] quality or compliance issue concerning Drug Substance, Drug Product or
the Services. Vir’s Quality Assurance Manager will arrange Vir audits with Biogen Quality Management. Audits shall be designed to minimize disruption of operations at the Facility. 

5.4.2 Additional Observation Rights. Upon at least [***] prior notice, from time to time, but no more frequently than
[***] every [***] (or such other period as is stated in an SOW), Vir may, subject to subcontractor contractual restrictions if applicable to any Third Party Facility, send up to [***] to the Facility [***] to observe the
Services for a period not to exceed [***] (or such other period as is stated in an SOW). 
 5.4.3 Visitation Terms. Vir’s
Representatives shall be required to sign Biogen’s standard visitor confidentiality agreement prior to being allowed access to the Facility. Such Representatives shall comply with the Facility’s rules and regulations for visitors. Vir
shall [***]. 
 5.5 Quality Agreement. Prior to the Manufacture or Fill Finish by Biogen of any Drug Substance or Drug Product required to be
Manufactured or Fill Finished in accordance with cGMP, including materials to be used in human clinical trials, the Parties shall negotiate in good faith and enter into a quality agreement starting from Biogen’s standard template or as
otherwise agreed by the Parties (“Quality Agreement”). If determined necessary by Biogen or Vir, the Parties shall enter into separate Quality Agreements for different Facilities. In the event of a conflict between any of the
provisions of this Agreement or an SOW and the Quality Agreement with respect to quality-related activities, including compliance with cGMP, the provisions of the Quality Agreement shall govern. In the event of a conflict between any of the
provisions of this Agreement or an SOW and the Quality Agreement with respect to any commercial matters, including allocation of risk, liability and financial responsibility, the provisions of this Agreement or the SOW (per the order of precedence
set forth in Section 2.1.1) shall govern. For clarity, this Section 5.5 only applies to Technology Transfer Services and Manufacturing Services. 

  
 17 

 5.6 Waiver of In Process Quality Control Holds. Project scheduling may include certain FDA
“Points to Consider” (PTC) assays and other in-process assays, as set forth in an SOW. PTC and in-process assays may prevent an SOW from progressing to
subsequent scheduled events until the results of these PTC and in-process assays are completed, documented and audited by the appropriate QC group. In the event that Vir wishes to expedite an SOW by proceeding
to subsequent project events without waiting for PTC and/or assay results, Vir shall provide Biogen with a written waiver referencing this Section 5.6 (“QC Hold Waiver”). If Biogen reasonably disagrees with
proceeding with Manufacturing under a QC Hold Waiver, Biogen may decline to proceed and will not be deemed to be in breach of its obligations hereunder while results are pending from the PTC or other
in-process assays and upon Vir written request Biogen shall describe the rationale for such disagreement in writing to Vir. If Biogen agrees to continue Manufacturing under a QC Hold Waiver, Biogen shall
remain responsible for activities and Services up to the QC Hold Waiver to the extent provided in this Agreement and such Manufacturing thereafter shall be at Vir’s risk. Vir shall [***]. Biogen shall remain responsible for activities up
to the QC Hold Waiver to the extent provided in this Agreement. For clarity, this Section 5.6 only applies to Manufacturing Services. 

5.7 Countries Subject to Restrictions. Biogen shall not be obliged to perform any Services which would involve any countries that are targeted by the
comprehensive sanctions, restrictions or embargoes administered by the United Nations, European Union, United Kingdom, or the United States of America. 

ARTICLE 6 

CONFIDENTIALITY AND NON-USE 

6.1 Definition. As used in this Agreement, the term “Confidential Information” includes all information furnished by or on behalf of
Biogen or Vir (the “Discloser”), its Affiliates or any of its or their respective Representatives, to the other Party (the “Recipient”), its Affiliates or any of its or their respective Representatives, whether
furnished before, on or after the Effective Date and furnished in any form, including written, verbal, visual, electronic or in any other media or manner and information acquired by observation or otherwise during any site visit at the other
Party’s facility. Confidential Information includes all proprietary technologies, know-how, trade secrets, discoveries, inventions and any other intellectual property (whether or not patented), analyses,
compilations, business or technical information and other materials prepared by either Party, their respective Affiliates, or any of its or their respective Representatives. For the avoidance of doubt, (a) all confidential information disclosed
under the Letter of Intent will be deemed Confidential Information of the applicable Discloser disclosed under this Agreement, and (b) the Biogen Proprietary Know-How is Biogen’s Confidential
Information. The existence and terms of this Agreement shall be deemed to be the Confidential Information of both Parties. The existence and terms of any future negotiations between the Parties (to the extent occurring during the Term) with respect
to a Commercial Supply Agreement or other potential contracts, including proposed pricing and other proposed contractual terms, shall be deemed to be the Confidential Information of both Parties. 

6.2 Exclusions. Notwithstanding Section 6.1, Confidential Information does not include information that (i) is or becomes
generally available to the public or within the industry to which such information relates other than as a result of a breach of this Agreement, (ii) is already known by the Recipient at the time of disclosure as demonstrated by the
Recipient’s written records, (iii) becomes available to the Recipient on a non-confidential basis from a source that is entitled to disclose it on a
non-confidential basis, or (iv) was or is independently developed by or for the Recipient without reference to the Confidential Information of the Discloser as evidenced by the Recipient’s written
records. 
 6.3 Mutual Obligation. The Recipient agrees that it will not use the Discloser’s Confidential Information except in connection with
the performance of its obligations hereunder and, with respect to Project Documentation and Manufacturing data, as set forth in Section 2.10.4, and will not disclose, without the prior written consent of the Discloser,
Confidential Information of the Discloser to any Third Party, except that the Recipient may disclose the Discloser’s Confidential Information: 

  
 18 

 6.3.1 to any of its Affiliates and its or their respective Representatives, and to its or
their contractors, that (i) need to know such Confidential Information for the purpose of performing under this Agreement, or in the case of Biogen’s potential contractors, for the purpose of evaluating whether or not to enter into a
subcontract for Services under this Agreement, (ii) are advised of the contents of this Article 6 and (iii) are bound to the Recipient by obligations of confidentiality at least as restrictive as the terms of this Article 6.
Each Party shall be responsible for any breach of this Article 6 by its Affiliates or any of its or their respective Representatives; 

6.3.2 to its actual and potential investors, acquirors, licensees and collaboration partners, in each case, to the extent such parties are
advised of the contents of this Article 6 and are bound to the Recipient by obligations of confidentiality at least as restrictive as the terms of this Article 6. Each Party shall be responsible for any breach of this Article 6
by any Third Party to whom it discloses under this Section 6.3.2; and 
 6.3.3 to the extent required by Applicable
Laws; provided that prior to making any such legally required disclosure, the Recipient shall give the Discloser reasonable prior notice of the requirement for and contents of such disclosure under the circumstances. Any such disclosure, however,
shall not relieve the Recipient of its obligations contained herein with respect to future disclosures of such Confidential Information. For clarity, any legally required disclosure of the terms of this Agreement or other subject matter that is
expressly described in Section 6.4 shall be subject to Section 6.4 instead of this Section 6.3.3. 

6.4 Publicity. Neither Party will disclose any terms of this Agreement or make a press release, announcement or engage in any other form of publicity
relating to the transactions which are the subject of this Agreement, or any ancillary matter, without first obtaining the prior written consent of the other Party. The Party wishing to make such disclosure, release, announcement or publicity will
provide a copy of the proposed text thereof to the other Party for its review and approval at least [***] prior to the proposed release. The reviewing Party may provide specific, reasonable comments on such release, announcement or publicity
reasonably in advance of the date of the proposed release, but will not unreasonably withhold or delay its approval to such release, announcement or publicity. Notwithstanding the foregoing, either Party may make such a disclosure to the extent
required by Applicable Laws or by the requirements of any nationally recognized securities exchange, quotation system or over-the-counter market on which such Party has
its securities listed or traded, provided that the disclosing Party make reasonable efforts to provide the other Party with reasonable notice beforehand and to coordinate with the other Party with respect to the wording and timing of any such
disclosure, including any redacted form of this Agreement required to be filed in connection therewith. In addition, Vir shall not use Biogen’s name in a manner that could be construed as an endorsement of Vir’s Drug Substance, or Drug
Product, including any scientific conclusion as to safety or efficacy. 
 6.5 No Implied License. Except as expressly set forth in Article 7,
the Recipient will obtain no right of any kind or license under any Confidential Information of the Discloser, including any patent application or patent, by reason of this Agreement. All Confidential Information will remain the sole property of the
Discloser, subject to Article 7. 
 6.6 Return of Confidential Information. Upon expiration or termination of this Agreement, or, solely with
respect to Project Documentation that comprises the Discloser’s Confidential Information, upon the expiration of any retention period required by Applicable Law, the Recipient will (and will cause its Affiliates and its and their respective
Representatives to) cease its use and, upon written request, within [***] either return or destroy (and certify as to such destruction) all Confidential Information of the Discloser, including any copies thereof, except for a single copy
which may be retained for the sole purpose of ensuring compliance with its obligations under this Agreement. 

  
 19 

 6.7 Return of Materials. Upon the earlier of expiration or termination of this Agreement or
completion of an SOW, Biogen shall upon Vir’s written request, return to Vir or destroy all Materials relating to such SOW, at Vir’s cost. If Vir has not provided authority regarding the disposition of Materials within [***] after
such termination, expiration or completion date, Biogen shall destroy the Materials. 
 6.8 Publication. Biogen shall not publish or otherwise
disclose to any Third Party the results of any use of the Materials without the prior express written consent of Vir, except that Biogen may use and disclose data associated with the Services (including gene expression levels achieved) if such data
is presented without any information directly or indirectly identifying Vir or its Intellectual Property. Vir shall not publish or otherwise disclose to any third person the results of any use of the Materials in combination with any Biogen
Confidential Information without the prior express written consent of Biogen. 
 6.9 Survival. The obligations of this Article will terminate
[***] from the expiration or termination of this Agreement, except with respect to trade secrets, for which the obligations of this Article will continue for so long as such information remains a trade secret under Applicable Law. 

6.10 Prior Confidentiality Agreement. This Agreement supersedes the Mutual Confidentiality Agreements between Vir and Biogen, dated on or about
[***], and any confidential information exchanged under such Confidentiality Agreement will be deemed Confidential Information hereunder, and will be subject to the terms of this Agreement. 

ARTICLE 7 
 INTELLECTUAL
PROPERTY 
 7.1 Definitions. For purposes hereof, “Intellectual Property” means all intellectual property (whether or not
patented), including patents, patent applications, know-how, trade secrets, copyrights, trademarks, designs, concepts, technical information, manuals, standard operating procedures, instructions,
specifications, inventions, processes, data, improvements and developments. “Vir IP” means all Intellectual Property and embodiments thereof owned by or licensed to Vir as of the date hereof or developed by Vir other than in
connection with this Agreement; “Biogen IP” means all Intellectual Property and embodiments thereof owned by or licensed to Biogen as of the date hereof or developed by Biogen other than in connection with this Agreement, including
the Biogen Proprietary Know-How, that are [***] for the Manufacture of the Drug Substance and/or Drug Product; “Invention” means any Intellectual Property developed by either Party or
jointly by the Parties in connection with this Agreement (including all SOWs and Change Orders under this Agreement); “Vir Invention” means any Invention other than an Improvement or a Biogen Process Invention that relates to the
Vir IP or to Vir’s Materials; and “Biogen Process Invention” means [***]. 
 7.2 Ownership of Intellectual
Property. All Vir IP and Vir Inventions shall be owned solely by Vir and no right therein is granted to Biogen under this Agreement, except as set forth in Section 7.5. All Improvements, Biogen IP and Biogen Process
Inventions shall be owned solely by Biogen and no right therein is granted to Vir under this Agreement except as set forth in Section 7.5. 

7.3 Assignment of Rights. If either Party develops an Invention that is the property of the other Party pursuant to
Section 7.2, the inventing Party shall notify the other Party. Each of Vir and Biogen shall, and does hereby, assign, and shall cause its Affiliates, employees, consultants and agents to so assign with full title guarantee,
to the other Party, without additional compensation, such right, title and interest in and to any Intellectual Property (including Inventions) as is necessary to fully effect the ownership provisions set out in Section 7.2,
and any accrued rights of action in respect thereof. Each of Vir and Biogen shall, if so requested by the other Party, execute all such documents and do all such other acts and things as may be reasonably required to comply with this
Section 7.3 to vest in the appropriate Party all rights in the relevant Intellectual Property and shall procure execution by any named inventor of all such documents as may reasonably be required by the other Party in
connection with any related patent application. 

  
 20 

 7.4 Patentable Inventions. In case any Inventions are patentable: 

7.4.1 the Party owning such Invention pursuant to Section 7.2 shall have the right, in its sole discretion, to
determine the patent strategy for such Invention, which may include not obtaining patent protection in a particular country or any country; 

7.4.2 the Party owning such Invention shall notify the other Party in writing at least [***] prior to filing any patent application
covering such Invention with respect to which a Representative of the non-owning Party is an inventor; 

7.4.3 without prejudice to the generality of Section 7.3, the Party not owning an Invention shall cooperate with the
other Party and/or its attorneys upon reasonable request, at the expense of the other Party, in (i) properly filing and prosecuting patent applications, (ii) vesting title herein provided and (iii) providing non-financial assistance in enforcing any patents resulting from such patent applications; and 
 7.4.4 the
cost of patenting Inventions will be borne by the owner of the Invention. 
 7.5 Licenses. 

7.5.1 License from Vir to Biogen. Vir hereby grants Biogen a non-exclusive, royalty-free, non-transferable worldwide license to all Vir IP and Vir Inventions that are necessary to perform Biogen’s obligations under this Agreement during the Term, and to perform any obligations of Biogen that survive
the expiration or termination of this Agreement. The foregoing license shall be sublicensable only to Biogen’s Affiliates and subcontractors for purposes of performing Biogen’s obligations under this Agreement. 

7.5.2 License from Biogen to Vir. Biogen hereby grants to Vir a non-exclusive, perpetual,
irrevocable, royalty-free, worldwide license under the Biogen IP and Biogen Process Inventions to use the Deliverables and any items transferred pursuant to Section 2.5 [***]. Vir agrees that it shall not
itself, and shall not permit its Affiliates or any Third Party to, reverse engineer or analyze any Biogen Proprietary Know-How or embodiments thereof with the objective of determining its composition of matter
or other characteristics. For clarity, this license shall survive termination or expiration of this Agreement. 
 7.5.3 License to
Improvements. Biogen hereby grants to Vir a non-exclusive, worldwide license under the Biogen IP and Biogen Process Inventions to use the Improvements [***] subject to Vir’s compliance
with [***]. 
 7.5.4 [***]. 

7.5.5 Sublicensing. The licenses set forth in Section 7.5.2 and 7.5.3 shall be sublicensable to
Vir’s Affiliates and to Vir’s or its Affiliates’ licensees of rights to Manufacture Drug Substance or Drug Products ([***]), and its and their respective contract manufacturers, provided that Vir notifies Biogen in writing in
advance of granting such sublicense and that the sublicensee, including each such contract manufacturer, enters into a confidentiality and limited use agreement (“CDA and Limited Use Agreement”) with Biogen in a form reasonably
acceptable to Biogen to protect the Biogen IP, Biogen Process Inventions, and any Biogen Confidential Information and other Biogen Intellectual Property rights in the Deliverables or other technology transfer items that are provided to such
sublicensee in connection with the sublicense. Biogen’s form of CDA and Limited Use Agreement as of the Effective Date is attached 

  
 21 

 
hereto as Attachment B. Vir acknowledges and agrees that it shall not conduct a technology transfer to, or Manufacture at, any Third Party facility using items that embody or incorporate
any Biogen IP or Biogen Process Inventions, or otherwise give any Third Party access to any Biogen IP or Biogen Process Inventions prior to the execution by such Third Party of a CDA and Limited Use Agreement in accordance with this
Section 7.5.5. [***]. 
 ARTICLE 8 

REPRESENTATIONS AND WARRANTIES 
 8.1
Biogen. Biogen represents, warrants and undertakes to Vir that, unless otherwise agreed to by the Parties in the SOW: 
 8.1.1 Biogen
has the full power and right to enter into this Agreement and there are no outstanding agreements, assignments, licenses, encumbrances or rights of any kind held by any Third Party, private or public, that are inconsistent with the provisions of
this Agreement; 
 8.1.2 Biogen shall perform all Services in accordance with all Applicable Laws; 

8.1.3 Biogen will not in the performance of its obligations under this Agreement use the services of any person debarred or suspended under 21
U.S.C. §335(a) or (b); 
 8.1.4 at the time of delivery by Biogen as provided in Section 2.10, Drug Substance
or Drug Product [***]; 
 8.1.5 with respect to each SOW, [***]; 

8.1.6 with respect to each SOW, [***]; and 

8.1.7 no transactions or dealings under this Agreement shall be conducted with or on behalf of an individual or entity that is designated as
the target of any sanctions, restrictions or embargoes administered by the United Nations, European Union, United Kingdom or the United States of America. 

8.2 Vir. Vir represents, warrants and undertakes to Biogen that: 

8.2.1 Vir has the full power and right to enter into this Agreement and except to the extent set forth in Section 4.6
under Vir’s agreement with [***], there are no outstanding agreements, assignments, licenses, encumbrances or rights of any kind held by any Third Party, private or public, that are inconsistent with the provisions of this Agreement;

 8.2.2 all Vir-supplied Materials shall have been produced, to Vir’s knowledge, in accordance
with Applicable Laws, shall comply with all applicable specifications, and shall not be adulterated, misbranded or mislabeled within the meaning of Applicable Laws; 

8.2.3 all Deliverables provided to Vir by Biogen shall be held, used and disposed of by or on behalf of Vir in accordance with all Applicable
Laws (including, in connection with any such items that are not labeled, 21 CFR § 201.150); specifically, Vir shall not permit the human consumption of any such items, except to the extent such consumption occurs in the course of clinical
trials that expressly permit such use and that have been approved by appropriate governmental authorities; and Vir will otherwise comply with all Applicable Laws applicable to Vir’s performance under this Agreement; 

  
 22 

 8.2.4 as of the Effective Date, Vir has all necessary authority to use and to permit Biogen
to use pursuant to this Agreement all Intellectual Property related to the Drug Substance, or Drug Product or Vir-supplied Materials (including artwork), and the performance of Services in connection with the
foregoing, including any copyrights, trademarks, trade secrets, patents, inventions and developments; there are no patents owned by others related to the Vir IP utilized with the Drug Substance, or Drug Product that would be infringed by Vir’s
performance of its obligations under this Agreement; and, to its knowledge, there are no trade secrets or other proprietary rights of others related to the Vir IP utilized with the Drug Substance, or Drug Product that would be infringed or misused
by Vir’s performance of this Agreement; 
 8.2.5 as of the Effective Date, Vir [***]; 

8.2.6 as of the Effective Date, Vir [***]. 

8.2.7 no transactions or dealings under this Agreement shall be conducted with or on behalf of an individual or entity that is designated as
the target of any sanctions, restrictions or embargoes administered by the United Nations, European Union, United Kingdom or the United States of America. 

8.3 Limitations. THE REPRESENTATIONS AND WARRANTIES SET FORTH IN THIS ARTICLE 8 ARE THE SOLE AND EXCLUSIVE REPRESENTATIONS AND WARRANTIES MADE BY
EACH PARTY TO THE OTHER PARTY AND NEITHER PARTY MAKES ANY OTHER REPRESENTATIONS, WARRANTIES OR GUARANTEES OF ANY KIND WHATSOEVER, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OR
FITNESS FOR A PARTICULAR PURPOSE. 
 ARTICLE 9 

INDEMNIFICATION 
 9.1 Indemnification by
Biogen. Biogen shall indemnify and hold harmless Vir, its Affiliates, and their respective directors, officers and employees (“Vir Indemnitees”) from and against any and all suits, claims, losses, demands, liabilities, damages,
costs and expenses (including reasonable attorneys’ fees and reasonable investigative and production costs) in connection with any suit, demand or action by any Third Party (“Losses”) arising out of or resulting from
(i) any breach of its representations, warranties or obligations set forth in this Agreement, including in connection with any Manufacture of Product or (ii) any negligence or willful misconduct by Biogen; in each case except to the extent
that any of the foregoing arises out of or results from any Vir Indemnitee’s negligence, willful misconduct or breach of this Agreement or the Quality Agreement, or Vir is obliged to indemnify a Biogen Indemnitee pursuant to Section 9.2.

 9.2 Indemnification by Vir. Vir shall indemnify and hold harmless Biogen, its Affiliates, and their respective directors, officers and employees
(“Biogen Indemnitees”) from and against any and all Losses arising out of or resulting from (i) any breach of its representations, warranties or obligations set forth in this Agreement, (ii) any manufacture, packaging,
sale, promotion, distribution, use of or exposure to Drug Substance, Drug Product or Vir-supplied Materials, including Losses on the basis of product liability or strict liability, (iii) the conduct of
any clinical trials utilizing any material or Drug Substance, or Drug Product which is the subject of this Agreement or any SOW, including any recalls relating to such clinical trials, (iv) any actual or alleged infringement or violation of any
Third Party patent, trade secret, copyright, trademark or other proprietary rights by Biogen’s use in accordance of this Agreement of Intellectual Property or other information or materials provided by Vir, including Vir-supplied Materials, or (v) any negligence or willful misconduct by Vir; in each case except to the extent that any of the foregoing arises out of or results from any Biogen Indemnitee’s negligence,
willful misconduct or breach of this Agreement or the Quality Agreement, or Biogen is obliged to indemnify a Vir Indemnitee pursuant to Section 9.1. 

  
 23 

 9.3 Indemnification Procedures. All indemnification obligations in this Agreement are conditioned
upon the Party seeking indemnification (i) promptly notifying the indemnifying Party of any claim or liability of which the Party seeking indemnification becomes aware (including a copy of any related complaint, summons, notice or other
instrument); provided, that failure to provide such notice within a reasonable period of time shall not relieve the indemnifying Party of any of its obligations hereunder except to the extent the indemnifying Party is prejudiced by such
failure, (ii) allowing the indemnifying Party, if the indemnifying Party so requests, to conduct and control the defense of any such claim or liability and any related settlement negotiations (at the indemnifying Party’s expense), (iii)
cooperating with the indemnifying Party in the defense of any such claim or liability and any related settlement negotiations (at the indemnifying Party’s expense) and (iv) not compromising or settling any claim or liability without prior
written consent of the indemnifying Party. 
 ARTICLE 10 

LIMITATIONS OF LIABILITY 
 10.1 TO THE
MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, BIOGEN SHALL HAVE NO LIABILITY UNDER THIS AGREEMENT FOR ANY AND ALL CLAIMS FOR LOST, DAMAGED OR DESTROYED
VIR-SUPPLIED MATERIALS, WHETHER OR NOT SUCH VIR-SUPPLIED MATERIALS ARE USED IN THE SERVICES OR INCORPORATED INTO DRUG SUBSTANCE OR DRUG PRODUCT. 

10.2 TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, BIOGEN’S TOTAL LIABILITY UNDER THIS AGREEMENT SHALL IN NO EVENT EXCEED [***]. 

10.3 TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE OR
CONSEQUENTIAL DAMAGES OR LOSS OF REVENUES, PROFITS OR DATA ARISING OUT OF PERFORMANCE UNDER THIS AGREEMENT, WHETHER IN CONTRACT OR IN TORT, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 

ARTICLE 11 
 INSURANCE

 Each Party shall, at its own cost and expense, obtain and maintain in full force and effect during the Term the following: (i) Commercial
General Liability Insurance with a per-occurrence limit of not less than [***]; (ii) Products and Completed Operations Liability Insurance with a per-occurrence
limit of not less than [***]; (iii) Workers’ Compensation Insurance with statutory limits and Employers Liability Insurance with limits of not less than [***] per accident; and (iv) [***]. Each Party may self-insure all or
any portion of the required insurance as long as, together with its Affiliates, its U.S. GAAP net worth is greater than [***] or its annual EBITDA (earnings before interest, taxes, depreciation and amortization) is greater than [***].
Each required insurance policy, other than self-insurance, shall be obtained from an insurance carrier with [***]. If any of the required policies of insurance are written on a claims made basis, such policies shall be maintained throughout
the Term and for a period of at least [***] thereafter. Upon the other Party’s written request from time to time, each Party shall promptly furnish to the other Party a certificate of insurance or other evidence of the required
insurance. 

  
 24 

 ARTICLE 12 

TERM AND TERMINATION 
 12.1 Term.
This Agreement shall commence on the Effective Date and shall continue for three (3) years or, if later, until the expiration or termination of all the SOWs, unless earlier terminated in accordance with Section 12.2 or
Section 12.3 (as may be extended in accordance with this Section, the “Term”). The Term shall automatically be extended for successive one (1) year periods unless and until one Party gives the other
Party at least [***] prior written notice of its desire to terminate as of the end of the then-current Term; provided that as long as any SOW is in effect, unless the terminating Party gives notice of its intent to terminate any SOW, the
terms of this Agreement shall remain in effect in respect of such SOW. 
 12.2 Termination by Vir Without Cause. Vir may terminate this Agreement or
any SOW without cause at any time during the Term on one hundred eighty (180) days’ prior written notice to Biogen. Upon receipt by Biogen of any such termination notice, Biogen will promptly cease or wind down, as appropriate, work under
the terminated SOW(s) unless otherwise requested by Vir in such notice. 
 12.3 Mutual Termination Rights. Either Party may terminate this Agreement
immediately without further action if (i) the other Party files a petition in bankruptcy, or enters into an agreement with its creditors, or applies for or consents to the appointment of a receiver, administrative receiver, trustee or
administrator, or makes an assignment for the benefit of creditors, or suffers or permits the entry of any order adjudicating it to be bankrupt or insolvent and such order is not discharged within [***], or takes any equivalent or similar
action in consequence of debt in any jurisdiction; or (ii) the other Party materially breaches any of the provisions of this Agreement, and such breach is not cured within [***] after the giving of written notice requiring the breach to
be remedied; provided, that in the case of a failure of Vir to make payments in accordance with the terms of this Agreement, Biogen may terminate this Agreement if such payment breach is not cured within [***] of receipt of notice of non-payment from Biogen. 
 12.4 Effect of Termination. Expiration or termination of this Agreement shall be without
prejudice to any rights or obligations that accrued to the benefit of either Party prior to such expiration or termination. In the event that this Agreement or any SOW is terminated, Vir shall, in connection with the terminated SOW(s), pay Biogen
for (i) the remainder of the Binding Forecast (except in the case of a termination by Vir under Section 12.3), (ii) for Manufacturing Services performed, and (iii) for all Development and any other non-Manufacturing Services performed up to the date of termination plus any applicable cancellation fees for incomplete Development and any other non-Manufacturing Services
pursuant to Section 3.1.7(b), and shall reimburse Biogen for all reasonable costs and expenses incurred, and all non-cancelable commitments made, in the performance of Services in
accordance with any ongoing SOW, including (i) reasonable out-of-pocket costs incurred to wind down and cease any ongoing Services and (ii) all costs for Vir-specific purchases made by Biogen pursuant to Section 3.1.5. Following the expiration or termination of this Agreement, Biogen shall transfer to Vir free of charge title in any readily
portable Procured Equipment and make such readily portable Procured Equipment available for removal by Vir at Vir’s expense. If Vir fails to make arrangements to remove such readily portable Procured Equipment within [***] after the date
of expiration or termination of this Agreement, Biogen shall be entitled to arrange for such removal for off-site storage or disposal, at Biogen’s discretion, and invoice Vir for reasonable removal costs
and any subsequent storage or disposal costs. To the extent Vir has not made payment for such Procured Equipment, the amounts due will be invoiced by Biogen on return and Vir will pay such invoice within [***] of receipt. For clarity, title
to any fixed, non-portable Procured Equipment located in the Facility shall remain with Biogen upon the expiration or termination of this Agreement at no cost to Biogen. Biogen shall have the right to dispose
of such Procured Equipment in its discretion. 
 12.5 Survival. All accrued rights of a Party, including Biogen’s accrued right to payments shall
survive the termination or expiration of this Agreement. The rights and obligations of the Parties under the following Sections and Articles shall survive the expiration or termination of this Agreement, in each case in accordance with their
respective terms (as applicable), 2.5 (Technology Transfer), 2.10.5 (Samples and Excess Materials), 3.1.7 (Cancellations and Postponements), 3.3 (Payment Terms), 3.4 (Method of Payment), 3.5 (Taxes), 5.1 (Recordkeeping), 6 (Confidentiality and Non-Use), 7 (Intellectual Property), 8.3 (Limitations), 9 (Indemnification), 10 (Limitations of Liability), 11 (Insurance), 12.4 (Effect of Termination), 12.5 (Survival), 13 (Notice), 14 (Miscellaneous), and the
definitions of all defined terms used in any of the foregoing. 

  
 25 

 ARTICLE 13 

NOTICE 
 All notices to be given as
required in the Agreement will be in writing and may be delivered personally or mailed either by a reputable express carrier with required receipt signature or certified mail, postage prepaid to the Parties at the addresses set forth below or at
such other address as either Party may provide by written notice to the other Party in accordance with the provisions of this Article 13. Such notice will be effective: (i) on the date sent, if delivered personally; (ii) the date
after delivery if sent by express carrier; or (iii) on the date received if sent by certified mail. Notwithstanding the foregoing notices of breach, termination or extension sent by email are not valid unless also sent by one of the other methods
stated herein. 
 If to Biogen: 

Biogen MA Inc. 
 Attn:
[***] 
 225 Binney Street 

Cambridge, MA 02142 

With a copy (which shall not constitute notice) to: 

Biogen MA Inc. 
 Attn:
[***] 
 225 Binney Street 

Cambridge, MA 02142 

If to Vir: 
 Vir
Biotechnology, Inc. 
 Attn: [***] 

499 Illinois Street, Suite 500 

San Francisco, CA 94158 
 Email:
[***] 
 ARTICLE 14 

MISCELLANEOUS 
 14.1 Entire Agreement;
Amendments. This Agreement, including the SOWs and any other attachments, any Quality Agreements executed hereunder, and any Change Orders or other amendments to any of the foregoing, and the Letter of Intent (solely with respect to the Prior
Development Activities and Confidential Information disclosed in connection therewith) constitutes the entire understanding between the Parties, and supersedes any contracts, agreements or understandings (oral or written) of the Parties, with
respect to the subject matter hereof. For the avoidance of doubt, this Agreement does not supersede any existing generally applicable confidentiality agreement between the Parties as it relates to time periods prior to the date hereof or to business
dealings not covered by this Agreement. No term of this Agreement may be amended in whole or in part by any Party or any Third Party, including by operation of law or order, except upon written agreement of both Parties, unless otherwise expressly
provided in this Agreement. 

  
 26 

 14.2 Captions; Interpretive Matters. The captions in this Agreement are for convenience only and are
not to be interpreted or construed as a substantive part of this Agreement. Unless otherwise expressly provided herein or the context of this Agreement otherwise requires, (i) words of any gender include each other gender, (ii) words such
as “herein,” “hereof” and “hereunder” refer to this Agreement as a whole and not merely to the particular provision in which such words appear, (iii) words using the singular shall include the plural, and vice
versa, (iv) the words “include(s)” and “including” shall be deemed to be followed by the phrase “but not limited to,” “without limitation” or words of similar import, (v) the word “or”
shall be deemed to include the word “and” (e.g. “and/or”) and (vi) references to “Article,” “Section,” “subsection,” “clause” or other subdivision, or to an Attachment or other
appendix, without reference to a document are to the specified provision or Attachment or other appendix of this Agreement. References to any laws, rules or regulations are to such laws, rules and regulations as they may be amended from time to
time. This Agreement shall be construed as if it were drafted jointly by the Parties. 
 14.3 Further Assurances. The Parties agree to execute,
acknowledge and deliver such further instruments and to take all such other incidental acts as may be reasonably necessary or appropriate to carry out the purpose and intent of this Agreement. 

14.4 No Waiver. Failure by either Party to insist upon strict compliance with any term of this Agreement in any one or more instances will not be deemed
to be a waiver of its rights to insist upon such strict compliance with respect to any subsequent failure. 
 14.5 Severability. If any term of this
Agreement is declared invalid or unenforceable by a court or other body of competent jurisdiction, the remaining terms of this Agreement will continue in full force and effect. 

14.6 Independent Contractors. The relationship of the Parties is that of independent contractors, and neither Party will incur any debts or make any
commitments for the other Party except to the extent expressly provided in this Agreement. Nothing in this Agreement is intended to create or will be construed as creating between the Parties the relationship of joint ventures, co-partners, employer/employee or principal and agent. Neither Party shall have any responsibility for the compensation of the other Party’s employees or contractors or for any employee benefits of any such
employee or contractor. 
 14.7 Successors and Assigns. This Agreement will be binding upon and inure to the benefit of the Parties, their successors
and permitted assigns. Neither party shall have any right to grant, assign or transfer to any Third Party by assignment, sale, grant, transfer, operation of law or otherwise, any rights or interest greater than the rights or interests granted to
such party under this Agreement. Neither Party may assign this Agreement, in whole or in part, including by operation of law or order, without the prior written consent of the other Party, except that [***]. Any permitted assignee shall
assume all obligations of its assignor under this Agreement and no assignment shall relieve any Party of responsibility for the performance of any obligation under this Agreement to the extent such obligation accrued prior to the data of assignment.
Any attempted assignment in violation of this Section 14.7 shall be null and void. 
 14.8 Performance Through Affiliates;
Sublicensee Guaranty; No Third Party Beneficiaries. Each Party may discharge any obligations and exercise any right hereunder through any of its Affiliates; provided, for clarity, that the license rights set forth in
Section 7.5.1 can only be executed by Vir’s Affiliates under a sublicense granted by Vir to such Affiliate pursuant to Section 7.5.5. Any Affiliate of Vir or Affiliate of Biogen may execute an
SOW under this Agreement, in which case, any reference to “Vir” in this Agreement shall mean such Affiliate of Vir and any reference to “Biogen” in this Agreement shall mean such Affiliate of Biogen for purposes of such SOW, and
such Affiliates shall be bound by the terms of this Agreement for purposes of such SOW. Each Party hereby guarantees the performance by its Affiliates of such Party’s obligations under this Agreement, and shall cause its Affiliates to comply
with the provisions of this Agreement in connection with such performance. Any breach by a Party’s Affiliate of any of such Party’s 

  
 27 

 obligations under this Agreement or any SOW (whether executed by a Party or its Affiliates) shall be deemed
a breach by such Party, and the other Party may proceed directly against such Party without any obligation to first proceed against such Party’s Affiliate. With respect to each sublicensee of Vir that executes a CDA and Limited Use Agreement
pursuant to the terms hereof, as between Vir and Biogen, Vir shall use commercially reasonable efforts to cause such sublicensee to comply with the provisions of CDA and Limited Use Agreement in connection with such performance and Vir
shall promptly report any breaches of such CDA and Limited Use Agreement to Biogen. This Agreement shall not confer any rights or remedies upon any person or entity other than the Parties named herein and their respective Affiliates, successors and
permitted assigns. 
 14.9 Governing Law. This Agreement, and all matters arising directly or indirectly hereunder, shall be governed by and construed
under the laws of the state of Delaware, USA, excluding its conflicts of law provisions. The United Nations Convention on Contracts for the International Sale of Goods shall not apply to this Agreement. 

14.10 Jurisdiction, Equitable Relief. 

14.10.1 Subject to Section 14.10.2, Biogen and Vir irrevocably and unconditionally consent to the exclusive
jurisdiction of the courts of the state of Delaware and the United States District Court for the state of Delaware for any action, suit or proceeding (other than appeals therefrom), and agree not to commence any action, suit or proceeding (other
than appeals therefrom) except in such courts, and hereby further irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an
inconvenient forum. [***]. 
 14.10.2 Biogen and Vir agree that irreparable damage may occur in the event of a breach of Article
6. It is accordingly agreed that each Party shall be entitled to seek an injunction or injunctions to prevent breaches of Article 6 and to enforce specifically the terms and provisions of such articles or sections of this Agreement in any
court of the U.S. or any state having jurisdiction, this being in addition to any other remedy to which they are entitled at law or in equity. Each Party hereby waives any requirement that any other Party post a bond or other security as a condition
for obtaining any such relief. 
 14.11 Right to Dispose and Set Off. If Biogen requests in writing from Vir direction with respect to disposal of any
inventories of Drug Substance, Drug Product, Vir-supplied Materials, other Materials, equipment, samples or other items belonging to Vir and is unable to obtain a response from Vir within [***], Biogen
shall be entitled in its sole discretion to (i) dispose of all such items and (ii) set-off any and all amounts due to Biogen or any of its Affiliates from Vir against any credits Vir may hold with
Biogen or any of its Affiliates. 
 14.12 Force Majeure. Except as to payments required under this Agreement, neither Party shall be liable in damages
for, nor shall this Agreement be terminable or cancelable by reason of, any delay or default in such Party’s performance hereunder if such default or delay is caused by events beyond such Party’s reasonable control, including acts of God,
law or regulation or other action or failure to act of any government or agency thereof, war or insurrection, terrorism, civil commotion, destruction of production facilities or materials by earthquake, fire, flood or weather, labor disturbances,
epidemic, pandemic or failure of suppliers, vendors, public utilities or common carriers; provided that the Party seeking relief under this Section shall promptly notify the other Party of such cause(s) beyond such Party’s reasonable control. A
Party that invokes this Section 14.12 shall use commercially reasonable efforts to perform its ongoing obligations to the other Party as soon as practicable. If the cause(s) shall continue unabated for [***], then
both Parties shall meet to discuss and negotiate in good faith what modifications to this Agreement should result from such cause(s). 

  
 28 

 14.13 Compliance with Anti-Corruption Laws. Each Party is aware of and understands that there are
anti-bribery and anti-corruption statutes (including but not limited to the U.S. Foreign Corrupt Practices Act) to which each Party is subject that prohibit, inter alia, the payment or offering, giving, promising to give, or authorizing the
giving of, directly or indirectly, anything of value to a government official, or any relative, business associate or employee thereof, for the purpose of obtaining or retaining any business under this Agreement or inducing or influencing any
governmental act or decision affecting either Party, and each Party shall ensure that, in connection with its obligations under this Agreement, it shall conduct their activities in a manner that is consistent with such statutes. 

14.14 Counterparts. This Agreement may be executed in one or more counterparts, each of which will be deemed an original but all of which together will
constitute one and the same instrument. Any photocopy, facsimile or electronic reproduction of the executed Agreement shall constitute an original. 

[Remainder of page intentionally blank; signature page follows] 

  
 29 

 IN WITNESS WHEREOF, the Parties have caused their respective duly authorized
representatives to execute this Agreement effective as of the Effective Date. 
  

			
	VIR BIOTECHNOLOGY, INC.
		
	By:	 	 /s/ George Scangos

	Name:	 	George Scangos
	Title:	 	President and CEO
	
	BIOGEN INC.
		
	By:	 	 /s/ Alphonse Galdes

	Name:	 	Alphonse Galdes
	Title:	 	EVP, PO&T

 [Signature Page to Development and Clinical Supply Agreement] 

 ATTACHMENT A 

STATEMENTS OF WORK 
 To be executed
from time to time by the Parties and attached hereto as successively numbered Attachments (e.g., Attachment A-1, A-2, A-3, etc.

 ATTACHMENT A-1 

Process Development SOW 

[Attached] 

 STATEMENT OF WORK 

 

			
	Title of Work Package
	 Statement of Work #1 for Development and Process & Analytical Establishment
of VIR SARS COV-2 mAb

	
	Agreement
	This “Statement of Work #1” (“SOW”) effective from the date of last signature (“Effective Date”) is made between VIR Biotechnology having offices at 499 Illinois Suite 500, San Francisco, CA
94158 (“VIR Biotechnology”). and Biogen, Inc., a Delaware corporation, with a place of business at 225 Binney Street, Cambridge, Massachusetts 02142, USA (“Biogen”).
	
	Agreement References
	 Clinical Development and Manufacturing Agreement (“CDMA”)

 
	  	This Statement of Work is subject to the terms of Clinical Development and Manufacturing Agreement between Biogen Inc. and VIR Biotechnology with an Effective Date of May 22, 2020, as amended
	 Quality Assurance Agreement
  
	  	[***]
	Purchase Order(s)	  	[***]

 COMPANY INFORMATION: 
  

			
	Site Addresses and Activities
	VIR Biotechnology SARS COV-2 mAb Drug Substance Development and Process/Analytical Establishment	  	Biogen Inc., 5000 Davis Drive, Durham, North Carolina, USA 27709; and 225 Binney St, Cambridge, MA 02142

 VIR Biotechnology CONTACTS: 
  

			
	Contact	  	Role
	[***]	  	[***]
	[***]	  	[***]

  
 Page 1 of 18 

 Attachment A-1 

 

	
	  

NOTE: Any changes in the scope of the project or financial terms of this project must be reviewed and approved by both the Primary VIR Biotechnology
Representative and VIR Biotechnology Technical Project Leader and the applicable Biogen representative. Except as expressly provided for in this Statement of Work #1, no additional payments to this Statement of Work #1 will be made without this
prior approval; otherwise VIR Biotechnology will not be liable for any costs incurred by Biogen.

 Effective from date of final signature 

Agreement 

 

 

					
	 Vir Biotechnology
	  		 	 Biogen, Inc.,

			
	 /s/ George Scangos
	  	    	 	 /s/ Alphonse Galdes

	Name: George Scangos	  		 	Name: Alphonse Galdes
	Position: CEO	  		 	Title: EVP PO&T
			
	Date: 22-May-2020	  		 	Date: 26-May-2020

  

			
	History of Change	  	Reason for Issue
		
	Version 0	  	First Issue

  
 Page 2 of 18 

 Attachment A-1 

Statement of Work #1 for Drug Substance 

Development and Process & Analytical 

Establishment of VIR Biotechnology
SARS-CoV-2 

mAB S309 Monoclonal Antibody 

For 
 VIR Biotechnology

  
 Page 3 of 18 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
			
	 1.
	 	 Statement of Work
	  	 	5	 
			
	 1.1
	 	Background	  	 	5	 
			
	 1.2
	 	Key Assumptions	  	 	5	 
			
	 1.3
	 	Project Timing:	  	 	5	 
			
	 1.4
	 	Unanticipated results:	  	 	5	 
			
	 2.
	 	 Services
	  	 	6	 
			
	 2.1
	 	Project Management	  	 	6	 
			
	 2.2
	 	[***]	  	 	6	 
			
	 2.3
	 	[***]	  	 	6	 
			
	 2.4
	 	[***]	  	 	6	 
			
	 2.5
	 	[***]	  	 	6	 
			
	 2.6
	 	[***]	  	 	6	 
			
	 2.7
	 	[***]	  	 	6	 
			
	 2.8
	 	[***]	  	 	6	 
			
	 2.9
	 	[***]	  	 	6	 
			
	 3.
	 	 Miscellaneous
	  	 	6	 
			
	 3.1
	 	Responsible persons	  	 	6	 
			
	 4.
	 	 Annexes
	  	 	8	 
			
		 	 Annex 1: Example Drug Substance Development Targets
	  	 	8	 
			
		 	 Annex 2: Pricing Schedule—Estimate
	  	 	9	 

  
 Page 4 of 18 

 Attachment A-1 

1. Statement of Work 
 1.1 Background

 This SOW (including the appendices, which are incorporated into and form part of this SOW) are subject to the provisions of the
Clinical Development and Manufacturing Agreement made between VIR Biotechnology and Biogen having an Effective Date of May 22, 2020 (the “Agreement”). 

The Product referred to in this SOW is VIR Biotechnology VIR
SARS-COV-2 MAB S309. 
 1.2 Key Assumptions 

[***]. 
 1.3 Project Timing:

 [***]. 
 1.4
Unanticipated results: 
 [***]. 

  
 Page 5 of 18 

 2. Services 

[***]. 
 2.1 Project
Management 
 Biogen will provide a Technical Project Manager who will serve as the primary point of contact for VIR Biotechnology. This
Project Managers will be responsible for the following, which will continue over the length of the program: 
 [***]. 

2.2 [***] 
 2.3 [***]

 2.4 [***] 
 2.5
[***] 
 2.6 [***] 

2.7 [***] 
 2.8 [***]

 2.9 [***] 
 3. Miscellaneous

 3.1 Responsible persons 
 [***]

  
 Page 6 of 18 

 Attachment A-1 

 

	4.	 Annexes 

Annex 1: Example Drug Substance Development Targets 

[***]. 

  
 Page 7 of 18 

 Attachment A-1 

Annex 2: Pricing Schedule—Estimate 
 [***]. 

  
 Page 8 of 18 

 Attachment A-1 

[***]. 

  
 Page 9 of 18 

 ATTACHMENT A-2 

Initial DS SOW 

[Attached] 

 STATEMENT OF WORK 

 

			
	 Title of Work Package

	Statement of Work #2 for Clinical Manufacturing of VIR SARS COV-2 mAb
	
	 Agreement

	This “Statement of Work #2” (“SOW #2”) effective from the date of last signature (“Effective Date”) is made between VIR Biotechnology having offices at 499 Illinois Suite 500, San Francisco,
CA 94158 (“VIR Biotechnology”). and Biogen, Inc., a Delaware corporation, with a place of business at 225 Binney Street, Cambridge, Massachusetts 02142, USA (“Biogen”).
	
	 Agreement References

	Clinical Development and Manufacturing Agreement (“CDMA”)	  	This Statement of Work #2 is subject to the terms of Clinical Development and Manufacturing Agreement between Biogen Inc. and VIR Biotechnology with an Effective Date of May 22, 2020, as amended
	Quality Assurance Agreement	  	To be developed
	Purchase Order(s)	  	[***]

 COMPANY INFORMATION: 
  

			
	 Site Addresses and
Activities

	VIR Biotechnology SARS COV-2 mAb Clinical Manufacturing	  	Biogen Inc., 5000 Davis Drive, Durham, North Carolina, USA 27709; and 225 Binney St, Cambridge, MA 02142

 VIR Biotechnology CONTACTS: 
  

			
	 Contact
	  	 Role

	[***]	  	[***]
		
	[***]	  	[***]
	
	 NOTE: Any changes in the scope of the project or financial terms of this project must be reviewed and approved by both the
Primary VIR Biotechnology Representative and VIR Biotechnology Technical Project Leader and the applicable Biogen representative. Except as expressly provided for in this Statement of Work #1, no additional payments to this Statement of Work #2 will
be made without this prior approval; otherwise VIR Biotechnology will not be liable for any costs incurred by Biogen.
  

  
 Page 1 of 6 

 Attachment A-2 

 

	1.	 Statement of Work 

 

	 	1.1.	 Background 

This SOW #2 is subject to the provisions of the Clinical Development and Manufacturing Agreement made between VIR Biotechnology and Biogen
having an Effective Date of May 22, 2020 (the “CDMA”). This Statement of Work #2 is deemed an SOW and is appended to the CDMA as Attachment A-2 pursuant to and governed by the terms of the CDMA
and is entered into by and between Biogen and VIR Biotechnology and is attached to the CDMA, incorporated therein and made fully a part thereof and sets forth details of the Services to be provided pursuant hereto. Capitalized terms not otherwise
defined by this SOW are deemed to have the meanings as defined in the CDMA. This SOW may not be altered, changed or amended except by a writing signed by each of the parties hereto as further set forth in the CDMA. 

This SOW #2 will be accompanied by a Manufacturing Request for Manufacturing Services by Vir pursuant to and governed by the terms of the CDMA
and is entered into by and between Biogen and VIR Biotechnology and is attached to the CDMA, incorporated therein and made fully a part thereof and sets forth details of the Services to be provided pursuant hereto. 

The Product referred to in this SOW #2 is VIR Biotechnology VIR
SARS-COV-2 MAB S309. 
  

	 	1.2.	 Services 

[***] 
  

	 	1.3.	 Summary Fees and Costs 

[***] 

  
 Page 2 of 6 

	 	1.4.	 Estimated Resin Cost 

[***] 
  

	 	1.5.	 Estimated Consumables & Raw Materials Cost 

[***] 
 Notwithstanding anything
herein that may be interpreted to the contrary, the Parties agree that upon execution of this SOW #2 and Manufacturing Request that this SOW #2 shall be subject to Section 12.4 of the CDMA. 

  
 Page 3 of 6 

 Attachment A-2 

 

									
	Biogen MA, Inc.,	 		  	Vir Biotechnology
					
	By:	 	 /s/ Alphonse Galdes 
	 		  	By:	  	 /s/ George Scangos

	Name: Alphonse Galdes, duly authorized	 	                    	  	Name: George Scangos
	Title: EVP Pharmaceutical Operations & Technology	 		  	Position: CEO
			
	Date: 26-May-2020	 		  	Date: 22-May-2020

  
 Page 4 of 6 

 Attachment A-2 

Schedule A 
 Process
Implementation Schedule (DRAFT) 
 [***]. 

  
 Page 5 of 6 

 ATTACHMENT A-3 

Intial DP SOW 

[Attached] 

 Attachment A-3 

STATEMENT OF WORK 
  

			
	 Title of Work Package

	 Statement of Work #3 for Clinical Drug Product Manufacturing of VIR SARS COV-2 mAb

	
	 Agreement

	This “Statement of Work #3” (“SOW #3”) effective from the date of last signature (“Effective Date”) is made between VIR Biotechnology having offices at 499 Illinois Suite 500, San Francisco,
CA 94158 (“VIR Biotechnology”). and Biogen, Inc., a Delaware corporation, with a place of business at 225 Binney Street, Cambridge, Massachusetts 02142, USA (“Biogen”).
	
	 Agreement References

	Clinical Development and Manufacturing Agreement (“CDMA”)	  	This Statement of Work #3 is subject to the terms of Clinical Development and Manufacturing Agreement between Biogen Inc. and VIR Biotechnology with an Effective Date of May 22, 2020, as amended
	Quality Assurance Agreement	  	To be developed
	Purchase Order(s)	  	[***]

 COMPANY INFORMATION: 
  

			
	 Site Addresses and
Activities

	 VIR Biotechnology SARS COV-2 mAb Clinical
Manufacturing
	  	Biogen Inc., 5000 Davis Drive, Durham, North Carolina, USA 27709; and 225 Binney St, Cambridge, MA 02142

 VIR Biotechnology CONTACTS: 
  

			
	 Contact
	  	 Role

		  	
	[***]	  	[***]
		  	
	[***]	  	[***]
		  	
	
NOTE: Any changes in the scope of the project or financial terms of this project must be reviewed and approved by both the Primary VIR Biotechnology Representative and VIR Biotechnology Technical Project Leader and
the applicable Biogen representative. Except as expressly provided for in this Statement of Work #1, no additional payments to this Statement of Work #2 will be made without this prior approval; otherwise VIR Biotechnology will not be liable for any
costs incurred by Biogen.
	

  
 49 

 1. Statement of Work 

1.1. Background 
 This SOW
#3 is subject to the provisions of the Clinical Development and Manufacturing Agreement made between VIR Biotechnology and Biogen having an Effective Date of May 22, 2020 (the “CDMA”). This Statement of Work #3 is deemed an SOW and is
appended to the CDMA as Attachment A-3 pursuant to and governed by the terms of the CDMA and is entered into by and between Biogen and VIR Biotechnology and is attached to the CDMA, incorporated therein and
made fully a part thereof and sets forth details of the Services to be provided pursuant hereto. Capitalized terms not otherwise defined by this SOW are deemed to have the meanings as defined in the CDMA. This SOW may not be altered, changed or
amended except by a writing signed by each of the parties hereto as further set forth in the CDMA. 
 This SOW #3 will be accompanied by a
Manufacturing Request for Manufacturing Services by Vir pursuant to and governed by the terms of the CDMA and is entered into by and between Biogen and VIR Biotechnology and is attached to the CDMA, incorporated therein and made fully a part thereof
and sets forth details of the Services to be provided pursuant hereto. 
 The Product referred to in this SOW #3 is VIR Biotechnology VIR SARS-COV-2 MAB S309. 
 1.2. Services 

[***] 
 1.3. Summary Fees and
Costs 
 [***] 
  

			
	Biogen MA, Inc.,	 	Vir Biotechnology
		
	 By: /s/ Alphonse Galdes 
	 	 By: /s/ George Scangos 

	Name: Alphonse Galdes, duly authorized	 	Name: George Scangos
	Title: EVP Pharmaceutical Operations & Technology	 	Position: CEO
		
	Date: 26-May-2020	 	Date: 22-May-2020

  
 50 

 ATTACHMENT B 

FORM OF CONFIDENTIAL DISCLOSURE AND LIMITED USE AGREEMENT 

[***]. 

  
 51 

 Exhibit A 

Selected Biogen Proprietary Know-How 

[***]. 

  
 52 

 ATTACHMENT C 

ACCESS FEES 
 Pursuant to
Section 3.1.3, Vir shall pay Biogen Access Fees for all successful Manufacturing of Drug Substance using any Improvements, regardless of whether such Manufacturing is performed directly by Vir, its Affiliates or its or
their licensees or collaborators or by Third Parties contracted by any of the foregoing. The entity performing such Manufacturing is referred to below as the “Manufacturer”. Access Fees are payable without regard to the amounts paid
by the purchaser of the Product to the Manufacturer. Access Fees apply to both pre-commercial/clinical and commercial-scale Manufacturing and will only be payable by Vir to Biogen on Successful Batches of
purified bulk Drug Substance. 
 The “Access Fee” is equal to [***]. [***]. 

  
 53 

 ATTACHMENT D 

INITIAL MANUFACTURING REQUEST 

  
 54

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]